

ARTICLE

WBP11 is required for splicing the TUBGCP6 pre-mRNA to promote centriole duplication

 Elizabeth M. Park¹, Phillip M. Scott¹, Kevin Clutario¹, Katelyn B. Cassidy² , Kevin Zhan¹, Scott A. Gerber^{2,3,4} , and Andrew J. Holland¹ 

Centriole duplication occurs once in each cell cycle to maintain centrosome number. A previous genome-wide screen revealed that depletion of 14 RNA splicing factors leads to a specific defect in centriole duplication, but the cause of this deficit remains unknown. Here, we identified an additional pre-mRNA splicing factor, WBP11, as a novel protein required for centriole duplication. Loss of WBP11 results in the retention of ~200 introns, including multiple introns in *TUBGCP6*, a central component of the γ -TuRC. WBP11 depletion causes centriole duplication defects, in part by causing a rapid decline in the level of *TUBGCP6*. Several additional splicing factors that are required for centriole duplication interact with WBP11 and are required for *TUBGCP6* expression. These findings provide insight into how the loss of a subset of splicing factors leads to a failure of centriole duplication. This may have clinical implications because mutations in some spliceosome proteins cause microcephaly and/or growth retardation, phenotypes that are strongly linked to centriole defects.

Downloaded from http://upress.org/jcb/article-pdf/219/1/e201904203/1455518/jcb_201904203.pdf by guest on 09 February 2026

Introduction

Centrioles are the core structural components of the centrosome, the cell's major microtubule-organizing center that arranges the interphase microtubule cytoskeleton in many cell types and forms the spindle poles during mitosis (Gönczy, 2012). Centrioles are also required to nucleate the axoneme of cilia that play critical roles in cell signaling, fluid movement, and locomotion. In cycling cells, centriole biogenesis is tightly coordinated with cell cycle progression (Firat-Karalar and Stearns, 2014; Nigg and Holland, 2018). At the start of the cell cycle, each cell contains a pair of parent centrioles. Centriole duplication begins at the G1-S transition, when one new procentriole forms at a single site perpendicular to each existing centriole. The procentriole remains engaged to the parent centriole in an orthogonal configuration and elongates during S and G2 phases. In mitosis, the procentriole disengages from the parent centriole so that each new daughter cell inherits a pair of centrioles that are competent for reduplication in the next cell cycle. Defects in centriole duplication can lead to the generation of excessive numbers of centrioles, promoting mitotic chromosome segregation errors and tumorigenesis in mice (Coelho et al., 2015; Levine et al., 2017; Serçin et al., 2016).

Polo-like kinase 4 (PLK4) is the earliest marker for the site of procentriole assembly and is initially recruited to form a ring around the proximal end of parent centrioles (Bettencourt-Dias et al., 2005; Habedanck et al., 2005; Sonnen et al., 2012). At the beginning of S phase, PLK4 transitions from a ring to a single "spot" that marks the site of procentriole assembly (Dzhindzhev et al., 2017; Kim et al., 2013; Ohta et al., 2014; Sonnen et al., 2012). This transformation is a symmetry-breaking reaction that requires the binding of PLK4 to its activator STIL (SCL/TAL1 interrupting locus; Arquint et al., 2015; Leda et al., 2018; Lopes et al., 2015; Moyer et al., 2015). Active PLK4 then phosphorylates STIL in two different regions to promote SAS6 and CPAP binding to initiate the assembly of the procentriole (Dzhindzhev et al., 2014; Kratz et al., 2015; Moyer et al., 2015; Moyer and Holland, 2019; Ohta et al., 2014). Phosphatases must counteract PLK4 activity, but the identity of the phosphatases responsible for controlling the initiation of centriole assembly remains unclear.

Control of centriole biogenesis depends on finely tuning the abundance of centriole duplication proteins. Overexpression of STIL or SAS6 leads to centriole overduplication and, accordingly,

¹Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH; ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH; ⁴Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Correspondence to Andrew J. Holland: aholland@jhmi.edu; K. Clutario's present address is Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA; K. B. Cassidy's present address is Discovery Sciences, Chemical Biology and Proteomics, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA.

© 2019 Park et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.upress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).

the levels of STIL and SAS6 are controlled by cell cycle-regulated protein degradation (Arquint and Nigg, 2014; Arquint et al., 2012; Strnad et al., 2007; Tang et al., 2011; Vlprecht et al., 2012). Centriole duplication is also extremely sensitive to the levels of PLK4; therefore, the abundance of the active kinase is tightly controlled by a negative feedback loop in which the dimeric kinase phosphorylates itself in trans to promote ubiquitination and degradation (Cunha-Ferreira et al., 2013; Guderian et al., 2010; Holland et al., 2010; Klebba et al., 2013). Along with posttranslational control of protein abundance, increasing evidence has linked posttranscriptional control of gene expression to the regulation of centriole biogenesis. Expression of the centriole proteins PLK4 and CP110 is downregulated by the binding of miRNAs to the 3' UTR of the mRNA (Bao et al., 2018; Cao et al., 2012; Song et al., 2014). Moreover, two alternative isoforms of CEP135 have been shown to play opposing roles in centriole biogenesis, and dysregulation of isoform expression promotes centrosome amplification in breast cancer cells (Dahl et al., 2015; Ganapathi Sankaran et al., 2019). A genome-wide RNAi screen revealed a strong connection between splicing factors and centriole biology, with 14 of 38 genes required for centriole biogenesis playing established roles in mRNA splicing (Balestra et al., 2013). Cells depleted of these splicing factors failed centriole duplication and progressed through the cell cycle to dilute out their centrioles through subsequent cell divisions. Recent work revealed that some splicing factors play direct roles in chromosome segregation in mitosis (Pellacani et al., 2018). Therefore, it remains unclear whether the splicing factors required for centriole assembly are needed for the correct splicing of a subset of pre-mRNAs necessary for centriole biogenesis or have roles independent of their function in splicing.

Here, we identify the pre-mRNA splicing factor WW domain-binding protein 11 (WBP11) as a novel protein required for centriole duplication. We show that WBP11 promotes the splicing of ~200 short introns with weak 5' splice sites. Our data indicate that one cause of the centriole biogenesis defects in WBP11-depleted cells is a rapid reduction in the levels of TUBGCP6, a core component of the γ -tubulin ring complex (γ -TuRC) that is required for the nucleation of centriolar microtubules (Bahtz et al., 2012). Importantly, this role in controlling the levels of TUBGCP6 is shared with multiple additional splicing factors that have previously been found to be required for centriole duplication (Balestra et al., 2013). Our study provides a molecular explanation for the essential role of a subset of splicing factors in centriole biogenesis.

Results

WBP11 is required for centriole duplication

It stands to reason that phosphatases act to antagonize PLK4 kinase activity, but the role of phosphatases in the control of centriole duplication remains poorly defined. To address this question, we performed an siRNA screen in human cells to identify protein phosphatases that function in centriole biogenesis. We used the pseudodiploid human colon cancer DLD-1 cell line and screened 254 genes encoding protein phosphatases

or phosphatase interacting proteins using a SMARTpool siRNA library (Table S1). Centriole number was assessed in mitotic cells 2 d after siRNA transfection (Fig. S1 A). To identify hits, we applied a threshold for values that were more than two times the SD from the mean centriole number in control cells. This resulted in 57 genes whose depletion led to the acquisition of five or more centrioles (centriole amplification) and 24 genes whose knockdown reduced centriole number to two or less (centriole loss; Fig. S1 B and Table S1). Increased activity of PLK4 leads to the production of a single parent centriole surrounded by multiple procenitrioles (Habedanck et al., 2005). By contrast, cytokinesis failure leads to cells entering into mitosis with four centrosomes, each containing a pair of centrioles. For the genes whose depletion caused centriole amplification, we never observed cells with a single parent centriole surrounded by multiple procenitrioles (data not shown). Instead, in cases where extra centrioles were observed, the configuration was consistent with what would be expected following cytokinesis failure. Since the centriole amplification phenotypes we observed are likely to have arisen from cytokinesis failure, we focused our attention on genes whose knockdown led to centriole loss.

The top centriole loss hit to emerge from the primary screen was the protein phosphatase 1 (PP1) binding protein WBP11. We performed a limited secondary screen in DLD-1, HeLa, and HCT116 cells, and depletion of WBP11 consistently ranked among the top hits that caused centriole duplication failure (Fig. S1, C–E; and Table S1). To our knowledge, WBP11 has not been previously implicated in centriole biogenesis and was therefore selected for further analysis.

Depletion of WBP11 in DLD-1 cells resulted in 80% of mitotic cells containing two or fewer centrioles by 72 h after siRNA transfection (Fig. 1, A and B). This phenotype was specific for WBP11 depletion, as it was observed with four independent WBP11 siRNAs (Fig. 1 C) and was almost fully rescued by expression of an siRNA-resistant WBP11-EYFP transgene (Fig. 1, E and F). Depletion of WBP11 in RPE-1 cells also caused a failure of centriole duplication, leading to 48% of mitotic cells with two or fewer centrioles by 72 h after siRNA transfection (Fig. S2, A and B). Together, these data show that WBP11 is required for centriole duplication and/or stability.

PP1 binding to WBP11 is not required for centriole biogenesis

Consistent with previous work, we found that WBP11 interacts with all three isoforms of the PP1 catalytic subunit (PP1 α , PP1 β , and PP1 γ ; Llorian et al., 2004; Fig. S2 C). WBP11 contains two putative RVxF PP1 binding motifs (Fig. S2 D). To test the requirement of these PP1 binding sites in centriole duplication, we created a WBP11 $^{\Delta PP1}$ -EYFP construct in which the two residues critical for PP1 binding (valine and phenylalanine) were mutated to alanine at both PP1 binding sites. As expected, the WBP11 $^{\Delta PP1}$ -EYFP mutant failed to coimmunoprecipitate with PP1 from cells (Fig. 1 D). To evaluate the effect of PP1 binding on centriole biogenesis, siRNA-resistant WT or PP1 binding-defective WBP11-EYFP transgenes were integrated at a predefined genomic locus in a DLD-1 host cell line. Surprisingly, both the WT and PP1 binding-defective WBP11-EYFP transgenes rescued centriole duplication to the same extent in cells depleted of




Figure 1. WBP11 is required for centriole duplication. **(A)** Immunoblot showing a time course of siRNA-mediated depletion of WBP11. **(B)** Quantification of centriole number in mitotic cells 72 h after siRNA-mediated depletion of either STIL or WBP11. $n = 3, \geq 49$ cells per experiment. Error bars represent SD. **(C)** Quantification of centriole number in mitotic cells 72 h after depletion of WBP11 with one of four independent siRNAs. $n = 3, \geq 47$ cells per experiment. Error bars represent SD. **(D)** Immunoblot showing coimmunoprecipitation (IP) of endogenous PP1 with WBP11^{WT}-EYFP, but not WBP11^{ΔPP1}-EYFP. **(E)** Immunoblot showing expression levels of WBP11-EYFP transgenes 72 h after transfection with a WBP11 siRNA. Cells were induced to express the WBP11-EYFP transgenes with doxycycline. **(F)** Quantification of centriole number in mitotic cells 72 h after siRNA-mediated knockdown of WBP11. Cells were induced to express an RNAi-resistant WBP11 transgene with doxycycline. $n = 4, \geq 47$ cells per experiment. Error bars represent SD. **(G)** Representative images of cells from F expressing an RNAi-resistant WBP11^{WT}-EYFP transgene. Scale bars represent 5 μ m; 1 μ m in zoomed-in region. **(H)** Representative images of cells from F expressing an RNAi-resistant, WBP11^{ΔPP1}-EYFP transgene. Scale bars represent 5 μ m; 1 μ m in zoomed-in region.

endogenous WBP11 (Fig. 1, E–H). We conclude that PP1 binding to WBP11 is not required for centriole duplication.

Acute depletion of WBP11 leads to centriole duplication failure and mitotic abnormalities

To monitor the acute effect of WBP11 loss on centriole number, we exploited the ability of the auxin-inducible degradation system to achieve rapid protein destruction in mammalian cells (Holland et al., 2012; Nishimura et al., 2009). A WBP11-mAID-EGFP transgene (mAID, mini-auxin-inducible degron) was integrated at a predefined genomic locus in DLD-1 cells, and endogenous WBP11 was then knocked out using CRISPR/Cas9-mediated gene targeting (Fig. 2 A). The resulting *WBP11*^{−/−}; WBP11-mAID-EGFP DLD-1 cells are hereafter referred to as WBP11^{AID}. As a control, we used a clone of WBP11-mAID-EGFP-expressing cells that went through the same genome-editing procedure but failed to knock out the endogenous WBP11 gene, hereafter referred to as WBP11^{WT}. Addition of auxin led to the degradation of WBP11-mAID-EGFP, with >90% of the protein depleted in 4.5 h (Fig. S2 E). Degradation of WBP11-mAID-EGFP resulted in penetrant centriole duplication failure in WBP11^{AID}, but not WBP11^{WT}, cells: at 24 h after auxin addition, 82% of WBP11^{AID} mitotic cells contained two or fewer centrioles (Fig. 2, B and C).

To determine the effect of WBP11 loss on cell proliferation, we examined cell growth using a competition-based growth assay (Fig. 2 D). Centriole loss induced by centrinone treatment had little impact on the short-term growth of DLD-1 cells in this assay (Fig. 2 E). By contrast, the degradation of WBP11-mAID-EGFP reduced the proliferation of WBP11^{AID} cells by 80% but did not affect the growth of WBP11^{WT} cells (Fig. 2 F). Furthermore, although DLD-1 cells continued to proliferate in the absence of centrioles, degradation of WBP11-mAID-EGFP in WBP11^{AID} cells caused a proliferation arrest within 2 d of auxin addition (Fig. 2 F and Fig. S2 F). These data suggest that loss of WBP11 leads to proliferation defects that cannot be explained by centriole duplication failure alone.

To determine why the loss of WBP11 prevents cell proliferation, we filmed WBP11^{AID} cells by time-lapse microscopy following the addition of auxin. Whereas 97% of untreated cells divided normally (Fig. S2, G and H; and Video 1), auxin-treated cells exhibited a dramatic increase in mitotic duration and mitotic errors starting at ~600 min after auxin addition (Fig. 2, G and H; Fig. S2 H; and Video 2). In contrast to untreated cells (Fig. 2 H and Video 3), cells lacking WBP11 showed reduced centrosome-driven microtubule nucleation and were frequently arrested in mitosis with monopolar spindles (Fig. 2 H and Video 4).

The vast majority of these cells underwent mitotic slippage. These data show that the loss of proliferation following degradation of WBP11 occurs primarily as a result of severe cell division defects and not centriole duplication failure.

The WBP11 proximity interactome highlights a core role in pre-mRNA splicing

WBP11 is reported to be a nuclear protein, and, accordingly, we did not observe the WBP11-mAID-EGFP transgene localizing to the centriole or centrosome at any stage of the cell cycle (Fig. 3 A; Llorian et al., 2005). To better understand the role of WBP11 in centriole duplication, we conducted biotinylation-dependent proximity mapping (BioID) experiments using DLD-1 cells stably expressing a WBP11-BirA* transgene (Roux et al., 2012). We identified a set of 178 high-confidence proximity interaction partners for WBP11 (Table S2). Previous studies have implicated WBP11 in pre-mRNA splicing and, in accord with this function (Craggs et al., 2001; Llorian et al., 2004, 2005), the top enriched gene ontology (GO) terms for the high-confidence WBP11 proximity interactome were “mRNA processing” (false discovery rate [FDR] = 4.15×10^{-74}) and “RNA splicing” (FDR = 4.54×10^{-71} ; Fig. 3 B). Moreover, 35% (63 of 178) of the high-confidence proximity interactors we identified have putative or known roles in mRNA splicing (Fig. 3 C).

One of the most abundant proteins in the WBP11 proximity interactome was PQBP1, a known binding partner of WBP11 (Komuro et al., 1999). We used CRISPR/Cas9 to tag the C-terminus of both endogenous PQBP1 alleles with mAID-EGFP in DLD-1 cells (Fig. S3, A and B). Degradation of PQBP1 with auxin reduced the long-term growth of cells but did not affect centriole duplication (Fig. S3, C–F). We conclude that WBP11 binding to PQBP1 is not required for centriole duplication to occur.

Transcriptome-wide identification of introns whose splicing depends on WBP11

From our proximity interactome, we identified multiple pre-mRNA splicing factors, including SNW1 (Sundaramoorthy et al., 2014; van der Lelij et al., 2014), SON (Ahn et al., 2011), PRPF8 (Grainger and Beggs, 2005), and SLU7 (Frank and Guthrie, 1992), that have previously been shown to be required for centriole duplication (Balestra et al., 2013). Given that the GO analysis of our proximity interactome yielded a high fraction of RNA processing and splicing factors, we hypothesized that WBP11 indirectly regulates centriole duplication through the splicing of pre-mRNAs that encode centriolar proteins. To address this question, we performed mRNA-seq on











Figure 2. WBP11 is required for cell proliferation and timely progression through mitosis. **(A)** Schematic of WBP11^{AID} cell line design. A WBP11-mAID-EGFP transgene was mutated to be resistant to Cas9 cleavage and integrated into DLD-1 cells at a predefined genetic locus. Cells were then transduced with a lentivirus encoding Cas9 and an sgRNA targeting endogenous WBP11. Monoclonal cell lines were screened for loss of endogenous WBP11. **(B)** Immunoblot showing expression of the WBP11-mAID-EGFP transgene and its degradation after auxin addition. WBP11^{WT} cells express endogenous WBP11 and the WBP11-mAID-EGFP transgene, while WBP11^{AID} cells express only the WBP11-mAID-EGFP transgene. **(C)** Quantification of centriole number in mitotic cells 24 or 48 h after degradation of WBP11 with auxin addition or inhibition of PLK4 with centrinone. $n = 3$, ≥ 49 cells per experiment. Error bars represent SD. **(D)** Schematic of a competition growth assay. mCardinal-expressing cells were mixed in a 1:1 ratio with WBP11^{WT} or WBP11^{AID} cells and grown in auxin or centrinone for 5 d. Cells were then analyzed by flow cytometry for mCardinal expression and the ratio of mCardinal-positive to mCardinal-negative cells was determined by flow cytometry. Unt, untreated. **(E)** Quantification of relative growth of cells using the competition assay following 5 d of auxin treatment. Relative growth was determined by evaluating the fraction of mCardinal-positive cells in the treated compared with untreated populations. $n = 3$. Unpaired parametric *t* test. $*, P = 0.0160$; $****, P < 0.0001$. Error bars represent SD. **(F)** Growth assay showing the fold increase in cell number after auxin or centrinone addition. Data are means \pm SEM, $n = 3$, performed in triplicate. Error bars represent SEM. **(G)** Quantification of mitotic duration from time-lapse videos of WBP11^{AID} cells expressing H2B-iRFP. The x axis shows how long after addition of auxin WBP11^{AID} cells entered into mitosis. Blue dots mark cells that completed mitosis normally and red dots mark cells that underwent mitotic errors. $n = 3, \geq 77$ cells per experiment. **(H)** Representative frames from videos of WBP11^{AID} cells stably expressing H2B-iRFP (red) and RFP-tubulin (green). Cells were either untreated or treated with auxin to induce WBP11^{AID} destruction. Scale bars represent 15 μ m.

polyA-containing RNA isolated from DLD-1 cells 72 h after mock or WBP11 siRNA transfection. To exclude changes that may be caused by the siRNA transfection procedure or by off-targets of the WBP11 siRNA, we also isolated polyA-containing RNA from DLD-1 cells and WBP11^{AID} cells that were treated with auxin for 48 h. First, we identified genes whose expression increased or decreased by more than two SDs from the average in both the WBP11 RNAi and WBP11^{AID} samples (Table S3). This analysis identified 29 genes with decreased expression and 49 genes with increased expression. However, none of these genes had known roles in centriole biogenesis (Table S3).

Next, we examined differentially expressed isoforms in both the siRNA and AID datasets. We calculated the fraction of reads for a gene that maps back to each isoform in both the control and experimental sample. We then subtracted the value for each isoform obtained in control cells from the value obtained in cells depleted of WBP11. This produced a Δ Isoform score ranging from -1 to +1 that represents the change in splicing of an isoform after WBP11 depletion: a positive Δ Isoform score represents an isoform with increased expression, and a negative Δ Isoform score corresponds to an isoform with decreased expression (Fig. 4 A). We considered a hit to be any isoform with a Δ Isoform score more than two SDs above or below the average change in isoform expression. This analysis identified 72 isoforms with increased expression and 86 isoforms with decreased expression in both the WBP11 RNAi and auxin samples (Fig. 4, B and C; Fig. S4, A and B; and Table S4). The only centrosomal gene that was present in these hits was *NEDD1*. However, the *NEDD1* protein levels were not altered by WBP11 depletion (Fig. S4 C). Therefore, the differential expression of *NEDD1* isoforms cannot explain the centriole duplication failure caused by depletion of WBP11.


Since changes in differential gene and isoform expression could not readily explain the centriole duplication defects observed following the loss of WBP11, we analyzed the effect of WBP11 loss on the splicing of individual introns. We used IR-Finder to calculate an intron retention (IR) ratio that scores the frequency with which an intron is retained in an mRNA as a value from 0 to 1 (Middleton et al., 2017). We then subtracted the IRratio for each intron in control cells from the IRratio of the same intron in cells depleted of WBP11. This produced an IR difference (IRDif) score from -1 to +1 that represents the change

in IRratio after WBP11 depletion: a positive IRDif score corresponds to an intron that was retained more frequently, and a negative IRDif score corresponds to an intron was spliced more efficiently (Fig. 4 A). To be considered a hit, an intron had to have an IRDif score of ≥ 0.1 or ≤ -0.1 . This analysis revealed 569 introns (9% of total introns detected, 85% of all hits) and 1,299 introns (16% of total introns detected, 92% of all hits) with an IRDif score of ≥ 0.1 after WBP11 depletion by siRNA or auxin, respectively (Fig. 4, D and E; and Table S5). Importantly, we detected only a small number of intronic transcripts whose abundance was decreased following depletion of WBP11, showing that WBP11 is primarily required to promote the efficient splicing of a subset of introns.

35% of the introns retained in the WBP11 RNAi sample were also retained in the auxin-treated WBP11^{AID} samples, providing a high-confidence list of 199 introns in 164 genes that show increased retention of one or more introns following WBP11 depletion (Fig. S4 D). While 87% of WBP11 target genes possess a single intron that relies on WBP11 for efficient splicing, 13% of genes possess multiple introns that are significantly altered following WBP11 knockdown. Genes with greater numbers of introns have a higher probability of being affected by WBP11 knockdown because they are more likely to have at least one intron that requires WBP11 for correct splicing, and because the impact of having multiple partially retained introns increases with the number of introns a gene contains. To determine the effect of WBP11 depletion on each gene, we calculated Δ Splicing as the change in the fraction of completely spliced mRNA for each gene following WBP11 depletion (see Materials and methods; Fig. 4, A, F, and G; and Table S6). We identified 34 high-confidence genes with IR that showed a greater than three SD decrease in the amount of completely spliced mRNA following WBP11 depletion by either siRNA or auxin (Fig. S4 E and Table S6). Only 1 of these 34 genes, *TUBGCP6*, was a known centrosome protein (see below; Bahtz et al., 2012). These data show that WBP11 loss has a large impact on the splicing of a small number of pre-mRNAs.

WBP11 and SNW1 are required for the splicing of a common set of pre-mRNAs

SNW1 was identified as an abundant proximity-interacting partner of WBP11 (Fig. 3 C), and we confirmed that the



C WBP11 BiOID hits - splicing factors





Figure 3. The proximity interactome of WBP11 contains many splicing factors. (A) Representative image showing WBP11-mAID-EGFP localization in interphase (top panels) and mitosis (bottom panels). Scale bars represent 10 μ m. **(B)** A subset of the top enriched GO terms upon analysis of the WBP11 proximity interactome. PANTHER GO biological process complete analysis was used to calculate the fold enrichments and FDR values. **(C)** Schematic of known splicing proteins that were present in the WBP11-BirA proximity interactome plotted using Cytoscape. Only high-confidence hits are shown. Proteins with similar interaction profiles are colored the same. Line thickness represents the ratio calculated from the enrichment of WBP11-BirA versus BirA alone. $n = 4$. Raw data are shown in Table S2.

WBP11^{WT}-EYFP transgene coimmunoprecipitated with endogenous SNW1 in cells (Fig. 5 A). SNW1 is a pre-mRNA splicing factor that has previously been shown to be required for centriole duplication (Balestra et al., 2013; van der Lelij et al., 2014). After 72 h of SNW1 depletion by SMARTpool siRNA, 71% of cells contained two or fewer centrioles (Fig. 5, B–D). This phenotype was specific for SNW1 depletion as it was observed with four independent SNW1 siRNAs (Fig. S4 F). Since SNW1 and WBP11 interact in cells and produce similar phenotypes after siRNA depletion, we explored the possibility that these two proteins

may control the splicing of a common set of pre-mRNAs. To evaluate this, we performed mRNA-seq on cells depleted of SNW1 for 72 h and analyzed IR (Table S5). We found a larger subset of introns retained in SNW1-depleted cells compared with cells depleted of WBP11 (1,499 intron hits in 959 genes; Fig. 5 E). Interestingly, of the introns that increased in abundance in the WBP11 RNAi sample, 57.6% were identical to introns that increased in abundance in the SNW1-depleted cells (Fig. S4 D). Moreover, 44 genes showed a more than three SD decrease in the amount of completely spliced mRNA after

A




$$\Delta\text{Isoform}_A = \frac{\# \text{ reads (Isoform}_A\text{)}_{\text{Exp}}}{\# \text{ reads (Gene)}_{\text{Exp}}} - \frac{\# \text{ reads (Isoform}_A\text{)}_{\text{Ctl}}}{\# \text{ reads (Gene)}_{\text{Ctl}}}$$

$$\text{IRRatio}(I_n) = \frac{\text{Intronic abundance}}{\text{Intronic + Exonic abundance}} \quad (\text{See Ref Middleton et al., 2017})$$


$$\text{IRDif}(I_n) = \text{IRRatio}(I_n)_{\text{Exp}} - \text{IRRatio}(I_n)_{\text{Ctl}}$$

$$\Delta\text{Splicing}_{\text{Gene}} = [1 - \text{IRDif}(I_1)] \times \dots \times [1 - \text{IRDif}(I_n)]$$


B




C




D



E



F



G




Figure 4. WB11 is required for proper splicing of a subset of introns. (A) Schematic describing the RNA-seq analysis performed. For a given gene, the change in isoform expression ($\Delta\text{Isoform}$) was calculated by subtracting the fraction of reads for a gene that map back to an isoform in the control sample from the corresponding value in the experimental sample. IRratio was calculated using the IRFinder program and measures the frequency with which an intron is retained in an mRNA as a value from 0 to 1 (Middleton et al., 2017). IRDif was calculated by subtracting the IRratio of each intron in the control from the experimental condition. $\Delta\text{Splicing}$ was calculated by taking the IRDif for each intron and subtracting it from 1 to determine the fraction of mRNAs that are

correctly spliced for that intron. We then multiplied this value for each intron in an mRNA to determine the percentage of the mRNAs for each gene that are correctly spliced. **(B)** Classification of isoforms that were differentially expressed 72 h after WBP11 depletion by RNAi. The Δ isoform value for each isoform was plotted against fold change in gene expression. Isoforms with a more than two SD change in expression were considered hits. Colors indicate isoforms with increased (blue) or decreased (red) expression following WBP11 depletion. Raw data are shown in Tables S3 and S4. **(C)** Classification of isoforms that were differentially expressed 48 h after WBP11 degradation by addition of auxin. The Δ isoform value for each isoform was plotted against fold change in gene expression. Isoforms with a more than two SD change in expression were considered hits. Colors indicate isoforms with increased (blue) or decreased (red) expression following WBP11 depletion. Raw data are shown in Tables S3 and S4. **(D)** Classification of introns detected by mRNA-seq 72 h after WBP11 depletion by RNAi. The IRDiff score of each intron was plotted against the IRratio of that same intron in the control sample. Colors indicate introns that are excised more efficiently (blue), or retained more often (red), following WBP11 depletion. Raw data are shown in Table S5. **(E)** Classification of introns detected by mRNA-seq 48 h after WBP11 degradation by addition of auxin. The IRDiff score of each intron was plotted against the IRratio of that same intron in the control sample. Colors indicate introns that are excised more efficiently (blue), or retained more often (red), following WBP11 depletion. Raw data are shown in Table S5. **(F)** Plot showing the change in the fraction of completely spliced mRNA for each gene 72 h after WBP11 depletion by RNAi. Colors indicate three SDs above (blue) or below (red) the average level of mRNA splicing observed. Raw data are shown in Table S6. **(G)** Plot showing the change in the fraction of completely spliced mRNA for each gene 48 h after WBP11 degradation with auxin. Colors indicate three SDs above (blue) or below (red) the average level of mRNA splicing observed. Raw data are shown in Table S6.

siRNA-mediated depletion of WBP11 or SNW1 (Fig. 5 F, Fig. S4 E, and Table S6). These results show that WBP11 and SNW1 promote the removal of a specific subset of introns.

WBP11 promotes the splicing of TUBGCP6

Altogether, we identified 145 introns in 122 genes that were preferentially retained in all three experimental populations (WBP11 siRNA, SNW1 siRNA, and WBP11 auxin; Fig. S4 D and Table S5). Some of these genes, such as *RNF123*, have a single intron that is highly retained following WBP11 or SNW1 depletion, while other genes, such as *RECQL4* and *SREBF1*, show multiple retained introns (Fig. S5, A–C). Immunoblotting confirmed that defects in splicing led to the expected reduction in SREBF1 and RECQL4 protein levels (Fig. S5, D and E). Although most retained introns require both WBP11 and SNW1 for efficient splicing, there were some introns whose splicing depends on SNW1, but not WBP11 (Fig. S5, B and C).

To obtain insight into how WBP11 and SNW1 control centriole duplication, we compared the list of genes that are strongly dependent on both WBP11 and SNW1 for correct splicing with a list of known centrosome proteins (Alves-Cruzeiro et al., 2014). 23 genes across all three experimental conditions (WBP11 siRNA, WBP11 auxin degradation, and SNW1 siRNA) showed a more than three SD decrease in the amount of completely spliced mRNA (Fig. S4 E and Table S6). *TUBGCP6* was the only gene within this list known to localize to the centrosome. Correct splicing of the *TUBGCP6* pre-mRNA was decreased by 48% following WBP11 siRNA, 89% after WBP11 auxin degradation, and 65% following SNW1 depletion (Figs. 4, F and G; and 5 F). Moreover, the abundance of the *TUBGCP6* mRNA was also modestly depleted by 0.2–0.5-fold following loss of WBP11 or SNW1 (Table S3). Manual inspection of the mRNA-seq data aligned to the Integrated Genome Viewer revealed that cells depleted of WBP11 or SNW1 showed the retention of multiple introns toward the 3' end of the *TUBGCP6* mRNA, an effect that was confirmed by RT-PCR analysis (Fig. 6, A and B). *TUBGCP6* is an essential component of the γ -TuRC and has a direct role in promoting microtubule nucleation at the centrosome (Bahtz et al., 2012; Farache et al., 2018). Retention of introns at the 3' end of the *TUBGCP6* mRNA is expected to produce a truncated protein of ~170 kD that would be unable to bind to γ -tubulin. We tested whether the protein levels of *TUBGCP6* changed after

depletion of SNW1 or WBP11 and found that the abundance of *TUBGCP6* was dramatically reduced by 24 h after siRNA-mediated depletion of SNW1 or WBP11 (Fig. 6 C). A similar effect was observed in WBP11^{AID} cells after degradation of the WBP11-mAID-EGFP transgene (Fig. 6 D).

Depletion of TUBGCP6 leads to similar phenotypes as the loss of WBP11

To determine if depletion of *TUBGCP6* leads to a failure of centriole duplication in DLD-1 cells, we used CRISPR/Cas9 to tag the C-terminus of both endogenous *TUBGCP6* alleles with a mAID-EGFP degron (Bahtz et al., 2012). Degradation of *TUBGCP6* led to a pronounced failure of centriole duplication that was similar to that observed in WBP11^{AID} cells (Fig. 7, A–C). Cells depleted of *TUBGCP6* also exhibited mitotic defects similar to those observed following loss of WBP11, including reduced centrosome-driven microtubule nucleation and mitotic arrest with a monopolar spindle (Fig. 2, G and H; Fig. 7, E–G; and Videos 5 and 6). However, while WBP11^{AID} cells divided normally for ~600 min (10 h) after auxin addition before undergoing abnormal mitotic divisions, *TUBGCP6*^{AID} cells displayed mitotic abnormalities almost immediately following treatment with auxin (Figs. 2 G and 7 F). This is consistent with the loss of WBP11 indirectly affecting mitotic progression due to defects in the splicing of a limited set of pre-mRNAs. Analysis of mitotic divisions taking place at least 1,000 min after auxin addition showed that both WBP11- and *TUBGCP6*-depleted cells predominantly undergo mitotic slippage (Fig. 7 G). Similar to WBP11^{AID} cells, the mitotic deficits dramatically reduced the proliferation of cells depleted of *TUBGCP6* (Fig. 7 H). Auxin-induced degradation of *TUBGCP6* did not exacerbate the failure of centriole duplication observed in cells depleted of WBP11, suggesting these genes function in the same pathway (Fig. S4 G). We, therefore, considered *TUBGCP6* to be an attractive candidate to explain how WBP11 loss leads to defects in centriole biogenesis.

Expression of intronless *TUBGCP6* partially restores centriole duplication in cells lacking WBP11

To test the hypothesis that the failure of *TUBGCP6* pre-mRNA processing is causally linked to the failure of centriole duplication in cells depleted of WBP11, we generated a DLD-1 cell line




Figure 5. SNW1 interacts with WBP11 and is required for centriole biogenesis. (A) Immunoblot showing coimmunoprecipitation (IP) of endogenous SNW1 with *WBP11^{WT}*-EYFP and *WBP11^{ΔPP1}*-EYFP. **(B)** Immunoblot showing expression levels of STIL, SNW1, and WBP11 72 h after siRNA transfection. **(C)** Quantification of centriole number in mitotic cells 72 h after siRNA-mediated depletion of SNW1. Data are shown alongside the data for WBP11 and STIL from Fig. 1 B. $n = 3, \geq 49$ cells per experiment. Error bars represent SD. **(D)** Representative images of cells from C transfected with a WBP11 or SNW1 siRNA. Scale bars represent 5 μ m; 1 μ m in zoomed-in regions. **(E)** Classification of introns detected by mRNA-seq 72 h after SNW1 depletion by RNAi. The IRDif score of each intron was plotted against the IRRatio of that same intron in the control sample. Colors indicate introns that are excised more efficiently (blue), or retained more often (red), following SNW1 depletion. Raw data are shown in Table S5. **(F)** Plot showing the change in the fraction of completely spliced mRNA for each gene 72 h after SNW1 depletion with siRNA. Colors indicate three SDs above (blue) or below (red) the average level of mRNA splicing observed. Raw data are shown in Table S6.




Figure 6. WBP11 and SNW1 are required for proper splicing of the TUBGCP6 pre-mRNA. **(A)** Schematic of the *TUBGCP6* gene. The 3' end of the gene is expanded and aligned to Integrative Genomics Viewer (IGV) reads to highlight retained introns (*) observed after loss of WBP11 or SNW1. **(B)** RT-PCR analysis of splicing of *TUBGCP6* intron 21 following depletion of WBP11 or SNW1. Schematic shows the position of the primers used for PCR and the expected product size. **(C)** Immunoblot showing *TUBGCP6* expression levels over a 3-d period following WBP11 or SNW1 siRNA knockdown. **(D)** Immunoblot showing *TUBGCP6* expression levels in *WBP11*^{WT} or *WBP11*^{AID} cells after 1 or 2 d of auxin addition.


Downloaded from http://jcb.rupress.org/jcb/article-pdf/219/1/e201904203/1455181/jcb_201904203.pdf by guest on 09 February 2026

stably expressing an intronless version of *TUBGCP6*. We first examined the functionality of the *TUBGCP6* transgene by testing its ability to rescue centriole duplication following auxin-induced degradation of endogenous *TUBGCP6*. Expression of a *TUBGCP6* transgene fully rescued centriole duplication in auxin-treated *TUBGCP6*^{AID} cells, demonstrating that this transgene was able to functionally compensate for the loss of the endogenous protein (Fig. S5, F and G). Importantly, expression of this *TUBGCP6* transgene was also able to partially restore centriole duplication 48 h after RNAi-mediated depletion of WBP11 or SNW1 (Fig. 8, A–C). By contrast, expression of a *TUBGCP6* transgene had no effect on centriole biogenesis in cells depleted of the centriole protein STIL, indicating that a *TUBGCP6*


transgene cannot compensate for the loss of core centriole proteins. Expression of *TUBGCP6* was unable to rescue centriole biogenesis after 72 h of WBP11 depletion by siRNA (Fig. S5 H). Given that re-expression of intronless *TUBGCP6* failed to rescue centriole duplication completely, it is likely that loss of WBP11 affects additional factors required for centriole biogenesis. These results indicate that the defective synthesis of mature *TUBGCP6* protein is a contributor to the failure of centriole biogenesis in cells lacking WBP11 and SNW1.

The high-confidence WBP11 proximity interactome contained four pre-mRNA splicing factors that have previously been shown to be required for centriole duplication: SNW1, PRPF8, SLU7, and SON (Balestra et al., 2013; Table S2). Given that WBP11


A




C




B




D




E



F



G



H




Figure 7. TUBGCP6 depletion produces phenotypes similar to WBP11 loss. **(A)** Immunoblot showing expression of endogenously tagged TUBGCP6-mAID-EGFP and its degradation after auxin addition. In TUBGCP6^{AID} cells, both endogenous *TUBGCP6* alleles were tagged with mAID-EGFP. TUBGCP6^{WT} cells are shown as a control. **(B)** Representative images of endogenously tagged TUBGCP6-mAID-EGFP. Cells were either untreated or treated with auxin to induce TUBGCP6^{AID} destruction. Scale bars represent 5 μ m; 1 μ m in zoomed-in regions. **(C)** Quantification of centriole number in mitotic cells 24 h after TUBGCP6-mAID-EGFP degradation with auxin. Data are shown alongside the 24-h auxin degradation of WBP11^{AID} from Fig. 2C. $n = 3$, ≥ 50 cells per experiment. Error bars represent SD. **(D)** Representative frames from videos of TUBGCP6^{AID} cells stably expressing H2B-iRFP (red) and EGFP-tubulin (green). Cells were either untreated or treated with auxin to induce TUBGCP6^{AID} destruction. Scale bars represent 10 μ m. **(E)** Quantification of mitotic duration from time-lapse videos of TUBGCP6^{AID} cells expressing H2B-iRFP. The x axis shows the time in the video at which the untreated TUBGCP6^{AID} cells entered into mitosis. Blue dots mark cells that completed mitosis normally and red dots mark cells that underwent mitotic errors. $n = 3$, ≥ 100 cells per experiment. **(F)** Quantification of mitotic duration from time-lapse videos of TUBGCP6^{AID} cells expressing H2B-iRFP. The x axis shows the time after auxin addition that TUBGCP6^{AID} cells entered into mitosis. Blue dots mark cells that completed mitosis normally and red dots mark cells that underwent mitotic errors. $n = 3$, ≥ 100 cells per experiment. **(G)** Quantification of the types of mitotic errors observed in cells depleted of TUBGCP6 or WBP11 for all mitotic divisions after 1,000 min of auxin treatment (images and mitotic time for WBP11 cells shown in Fig. 2). Error bars represent SD. **(H)** Quantification of relative growth of cells using the competition assay following 5 d of auxin treatment. Relative growth was determined by evaluating the fraction of mCardinal-positive cells in the treated compared with untreated populations. $n = 3$. Unpaired parametric *t* test. *, $P = 0.0366$; ***, $P = 0.0006$; ****, $P < 0.0001$. Error bars represent SD.

and SNW1 are required for *TUBGCP6* pre-mRNA processing, we set out to test whether reduced levels of *TUBGCP6* protein may accompany centriole duplication failure in cells depleted of SON, PRPF8, or SLU7. Importantly, depletion of PRPF8 or SLU7 by siRNA significantly reduced *TUBGCP6* protein levels (Fig. 8D). Knockdown of SON led to rapid cell death and was not further analyzed. Importantly, expression of an intronless *TUBGCP6* transgene increased the fraction of cells with a normal centriole content 48 h after RNAi-mediated depletion of SLU7 or PRPF8, although for PRPF8 this increase did not reach statistical significance (Fig. 8, E and F). We conclude that *TUBGCP6* expression level is sensitive to alterations in the levels of some RNA splicing factors, partly explaining the requirement of these proteins in centriole biogenesis (Balestra et al., 2013).

WBP11-dependent introns possess weak splice sites

To elucidate the specificity of WBP11 regulation on mRNA splicing, we considered the possibility that WBP11 may be required for the splicing of suboptimal splice sites. We divided all introns from the WBP11 mRNA-seq experiment into six bins based on their IRratio in the control sample. For each of these six categories, we established the proportion of introns that had an IRDif score ≥ 0.1 and therefore required WBP11 for efficient splicing. If no bias was present, an increasing control IRratio would tend to reduce the IRDif score and, therefore, reduce the proportion of introns with an IRDif score ≥ 0.1 . However, we observed that the probability an intron would be retained generally increased as the control IRratio increased from 0 to 0.5, and a similar trend was observed following auxin-induced degradation of WBP11 (Fig. 9, A and B). This suggests that introns that are poorly spliced in control cells are more likely to be significantly retained following WBP11 depletion.

Previous work has shown that 5' splice sites are critical elements in determining the efficiency of intron-splicing reactions (Roca et al., 2013; Wickramasinghe et al., 2015). To elucidate the specificity of WBP11-dependent RNA splicing, we examined the difference in 5' splice site strength between a high-confidence list of introns that are retained after WBP11 depletion (IRDif ≥ 0.1 following WBP11 depletion) and those that are correctly spliced (IRDif ≥ -0.1 and ≤ 0.1 following WBP11 depletion). 5' splice site strength was estimated for each intron by

calculating maximum entropy (MAXENT) scores that predict the likelihood a given splice site will be used (Yeo and Burge, 2004). Consistent with prior work suggesting that IR correlates with lower splice site strength, introns with IRDif values of ≥ 0.1 had weaker 5' splice sites (Fig. 9C; Sakabe and de Souza, 2007). WBP11-dependent introns were also significantly shorter in length (Fig. 9D). 5' splice site strength and intron size both decreased as the degree of IR increased (Fig. 9, C and D). Taken together, this suggests that short introns with weak 5' splice sites show an increased dependence on WBP11 for efficient recognition by the splicing machinery.

Discussion

The vast majority of protein-coding transcripts in human cells must undergo splicing before they can serve as functional templates for protein synthesis. Splicing is therefore essential for all cellular processes, and global defects in spliceosome function are expected to lead to rapid cell-autonomous lethality. Surprisingly, however, a recent genome-wide RNAi screen identified 14 splicing factors that are required for centriole duplication in human cells. It is unclear why mutations in broadly expressed genes encoding spliceosome components result in the specific phenotype of centriole duplication failure.

In this article, we demonstrate a requirement for the pre-mRNA splicing factor WBP11 in centriole biogenesis. WBP11 was required to facilitate efficient splicing of 199 introns. These introns were present in 164 genes and were not enriched in genes of a particular biological pathway or function. Importantly, many of the pre-mRNAs that depend on WBP11 for efficient splicing also require SNW1, a pre-mRNA splicing factor that interacts with WBP11 and was previously shown to be important for centriole duplication. This suggests that SNW1 and WBP11 are required for splicing a subset of introns residing in the pre-mRNA of one or more genes required for centriole function.

Our experiments indicate that reduction in WBP11 or SNW1 leads to defects in centriole duplication in part because of loss of *TUBGCP6* protein, thereby providing a molecular explanation for the role of these splicing factors in centriole biogenesis. Several lines of evidence support this conclusion. First, loss of




Figure 8. Expression of intronless TUBGCP6 can partially rescue centriole duplication failure after WBP11 depletion. **(A)** Immunoblot showing TUBGCP6 levels after 48 h of siRNA-mediated depletion of SNW1 or WBP11. Cells on the right expressed the FLAG-TUBGCP6 transgene. **(B)** Quantification of centriole number in mitotic cells after siRNA-mediated knockdown of SNW1 or WBP11 for 48 h. FLAG-TUBGCP6 transgene was induced with doxycycline where indicated. $n = 3$ (SNW1 and STIL), $n = 4$ (control and WBP11), ≥ 50 cells per experiment. Error bars represent SD. **(C)** Graph showing the percentage of mitotic cells with three to four centrioles, as shown in Fig. 8 B. Unpaired parametric t test: *, $P = 0.0343$ (WBP11) and 0.0353 (SNW1). Error bars represent SD. **(D)** Immunoblot showing the levels of TUBGCP6 48 h after siRNA-mediated depletion of WBP11, PRPF8, or SLU7. **(E)** Quantification of centriole number in mitotic cells after siRNA-mediated knockdown of WBP11, PRPF8, or SLU7 for 48 h. FLAG-TUBGCP6 transgene was induced with doxycycline where indicated. $n = 6$, ≥ 50 cells per experiment. Error bars represent SD. **(F)** Graph showing the percentage of mitotic cells with three to four centrioles, as shown in Fig. 8 E. Unpaired parametric t test: *, $P = 0.0429$ (WBP11) and 0.0115 (SLU7). Error bars represent SD.

Downloaded from https://academic.oup.com/jcb/article/pdf/2019/11/e201904203/1455151/jcb.201904203.pdf by guest on 09 February 2020

TUBGCP6, WBP11, and SNW1 share phenotypic similarities, including the formation of monopolar spindles, a prolonged mitosis, and centriole duplication failure. Second, we detected aberrant processing of the TUBGCP6 pre-mRNA and severely

reduced levels of TUBGCP6 protein in WBP11- and SNW1-depleted cells. Finally, expression of an intronless TUBGCP6 transgene partially rescued the centriole duplication failure phenotype in WBP11- or SNW1-depleted cells. Given that




Figure 9. WBP11 is required for splicing short introns with weak 5' splice sites. (A and B) Introns from the WBP11 RNAi RNA-seq experiment (A) or the WBP11 auxin RNA-seq experiment (B) were divided into six bins based on their IRratio in the control sample. For each bin, we calculated the fraction of introns that required WBP11 for efficient splicing (IRDif score ≥ 0.1). The probability an intron would be retained generally increased as the control IRratio increased from 0 to 0.5. Therefore, introns that are weakly spliced in the control sample are more likely to be retained following WBP11 depletion. **(C)** Violin plots of MAXENT splice site scores of introns that are significantly retained following WBP11 RNAi and degradation with auxin. Introns were divided into groups based on their IRDif scores. No change = IRDif ≥ -0.1 and ≤ 0.1 . Introns that are more highly retained (larger IRDif values) following depletion of WBP11 have weaker splice site scores (lower MAXENT values). Points represent the mean and bars display the SD. P values were calculated using an unpaired parametric t test. **(D)** Violin plots showing the length of the introns that are significantly retained following WBP11 RNAi and degradation with auxin. Introns were divided into groups based on their IRDif scores. No change = IRDif ≥ -0.1 and ≤ 0.1 . Introns that are more highly retained (larger IRDif values) following depletion of WBP11 are smaller in size. Points represent the mean and bars display the SD. P values were calculated using an unpaired parametric t test.

depletion of at least 13 additional splicing factors also leads to defects in centriole biogenesis (Balestra et al., 2013), it is tempting to speculate that compromised processing of the TUBGCP6 pre-mRNA may be a common defect contributing to centriole duplication failure in cells depleted of select splicing factors. Consistent with this hypothesis, depletion of SLU7 and PRPF8, two pre-mRNA splicing factors that are required for centriole duplication and are present in the WBP11 proximity interactome, also decreased the protein levels of TUBGCP6. In addition, the failure of centriole duplication in cells depleted of SLU7 and PRPF8 was partially rescued by expression of a cDNA encoding TUBGCP6.

Perhaps unsurprisingly, expression of an intronless TUBGCP6 cDNA was unable to fully rescue the phenotypes incurred by depletion of WBP11 or SNW1. This is not due to deficiencies in the functionality of the TUBGCP6 transgene, as this transgene could fully rescue loss of the endogenous TUBGCP6 protein. Instead, our data suggest that the defective splicing of other pre-

mRNAs contributes to the effects observed following depletion of WBP11 or SNW1. One of the pre-mRNAs most affected by depletion of WBP11 and SNW1 encodes CPSF1, a component required for cleavage and polyadenylation at the 3' end of pre-mRNAs (Murthy and Manley, 1995). Depletion of CPSF1 is expected to negatively impact the expression of many proteins, highlighting how defective splicing of a relatively small number of pre-mRNA targets can indirectly result in larger changes in gene expression. This may explain why the ability to rescue centriole duplication with the intronless TUBGCP6 transgene is reduced if cells lacking WBP11 or SNW1 are analyzed at later time points after siRNA transfection.

We show that reducing the levels of WBP11 preferentially alters the splicing of only a subset of short introns that contain weak 5' splice sites. Weak and strong splice sites compete for binding to the spliceosome complex (Munding et al., 2013). It is possible that WBP11 functions to facilitate the binding of the spliceosome to weak 5' splice sites. An alternative and non-mutually exclusive model is that depletion of WBP11 reduces the

concentration/activity of the core spliceosome, leading to alterations in the kinetic equilibrium of spliceosome assembly at strong and weak splice sites, the ultimate consequence of which is an enhanced selection of strong splice sites. We note that some transcripts with retained introns may be rapidly degraded by the nonsense-mediated mRNA decay pathway and would not be detected in our analysis.

IR was traditionally considered to be the consequence of mRNA missplicing. However, recent work has shown IR to be a physiological mechanism of controlling gene expression in diverse processes such as neurogenesis (Braunschweig et al., 2014; Buckley et al., 2011) and hematopoiesis (Wong et al., 2013). In these cases, downregulation of splicing factors leads to the retention of specific introns and reduced expression of a subset of genes. A recent study showed that the temporal control of IR could also provide a mechanism for establishing the timing of gene expression during the cell cycle (Dominguez et al., 2016). One transcript identified to be alternatively spliced in this study was TUBGCP6, which shows preferential retention of an intron in a cell cycle-controlled manner. It is thus plausible that IR in TUBGCP6 mRNA is a regulated process that functions to control the activity of the γ -TuRC and tune the microtubule nucleating capacity of the cell.

The phenotypic link we have described between defects in the splicing machinery and centriole duplication may have clinical significance. The minor spliceosome is responsible for catalyzing the removal of atypical U12-type introns, and mutations in components of this complex have been linked to developmental disorders characterized by microcephaly and dwarfism (Farach et al., 2018; He et al., 2011; Merico et al., 2015). Given that mutations in centriole and centrosome proteins cause developmental disorders that include very similar phenotypes (Chavali et al., 2014), it is tempting to speculate that defects in centriole biogenesis may contribute to the disease pathology in syndromes caused by mutations in splicing factors. In the future, it will be interesting to further explore this relationship by examining centriole number in clinical samples of patients with splicing factor mutations.

Materials and methods

Cell culture and maintenance

All cell lines were grown at 37°C with 5% CO₂ and maintained in DMEM (Corning) containing 10% fetal bovine essence (Seradigm), 100 U/ml penicillin, 100 U/ml streptomycin, and 2 mM L-glutamine. Flp-In TRex-DLD-1 cells were used in all experiments, with the exception of Fig. S2, A and B, where RPE1 cells were used, and cotransfection experiments, where HEK293FT cells were used. Stable, isogenic Flp-In TRex-DLD-1 cell lines expressing transgenes from a cytomegalovirus promoter were generated using XtremeGene HP and selected for transgene incorporation using Hygromycin (Corning) at a concentration of 400 μ g/ml. Transgene expression was induced using 1 μ g/ml of tetracycline (Sigma-Aldrich). Flp-In TRex-DLD-1 cells and RPE1 cells lines were authenticated using short tandem repeat genotyping.

For RNAi, cells were seeded at 10⁵ cells per milliliter of medium. Duplexed siRNAs were introduced at a final concentration

of 100 nM using RNAiMAX (Life Technologies). siRNA directed against STIL (5'-GCUCAAACAGUUUCUGCUGGAAU-3') was purchased from GE Healthcare, a SMARTpool set of four siRNAs directed against WBP11 was purchased from Dharmacon and siRNA #1 (5'-CGUGAAACCUUUGAACGUA-3') was used for further experiments, and a SMARTpool set of four siRNAs against SNW1 was purchased from Dharmacon and siRNA #1 (5'-GGAAAUGCGUGCCCAAGUA-3') was used for further experiments. Immediately after transfection, tetracycline was added to induce expression of WBP11-EYFP. 72 h after transfection, cells were harvested for Western blot or fixed for immunofluorescence analysis unless otherwise indicated.

Phosphatase screen

Cells were transfected with Dharmacon ON-TARGETplus SMARTpool siRNA Library-Human Phosphatase against a total of 254 genes following the protocol outlined above. Sequences of the siRNA duplexes used can be found in Table S1. 48 h after transfection, cells were fixed in MeOH at -20°C and incubated for 1 h with centrin and CEP192 antibodies. Cells were imaged using a DeltaVision microscope at 60 \times magnification, and centrioles were quantified in mitotic cells. Genes that resulted in significant centriole underduplication (greater than two times the SD than in control cells) were validated in DLD-1, HeLa, and HCT-116 cells at 48 h after transfection following the same transfection protocol. The top hit, WBP11, was further quantified at up to 72 h following transfection.

Lentiviral production and transduction

To create lentivirus, the lentiGuide-Puromycin (52963; Addgene) plasmid was cotransfected into HEK293FT cells with the lentiviral packaging plasmids psPAX2 and pMD2.G (12260 and 12259; Addgene). Briefly, 3 \times 10⁶ HEK293FT cells were seeded into a poly-L-lysine-coated 10-cm culture dish 24 h before transfection. For each 10-cm dish, 4.5 μ g of lentiviral vector, 6 μ g of psPAX2, and 1.5 μ g of pMD2.G were diluted into 0.6 ml OptiMEM (Thermo Fisher Scientific). Separately, 35 μ l of 1 μ g/ μ l 25-kD polyethylenimine (Sigma-Aldrich) was diluted into 0.6 ml OptiMEM, mixed, and incubated at room temperature for 5 min. The DNA and polyethylenimine mixtures were then combined, mixed, and incubated at room temperature for 20 min. During this incubation, the culture medium was replaced with 9 ml prewarmed DMEM + 1% FBS (Sigma-Aldrich). The transfection mixture was added dropwise to the 10-cm dish. Viral particles were harvested 48 h after the medium change and filtered through a 0.45- μ m polyvinylidene fluoride syringe filter. The filtered supernatant was either used directly to infect cells or was snap frozen and stored at -80°C. For transduction, 1 ml of virus was added to cells grown in 9 ml of DMEM containing 10 μ g/ml polybrene (Sigma-Aldrich).

WBP11-mAID cell line production

A WBP11-mAID-EGFP transgene with mutations at the protospacer-adjacent motif site that render it immune to Cas9 cleavage was integrated at a stable locus in Flp-In TRex-DLD-1 cells that express osTIR1-9xMyc. Stable Flp-In cell lines expressing WBP11-mAID-EGFP were generated as described above.

WBP11-mAID-EGFP cells were grown continuously in the presence of tetracycline, and Cas9 along with a single gRNA (sgRNA) targeting endogenous WBP11 (5'-ACCTGCCATACGAAGCATCA-3') was introduced into the cells using lentiviral transduction. Cells were selected using puromycin (2 µg/ml), passaged into limiting dilution, and clones were screened via Western blot to confirm knockout of WBP11. Degradation of the AID transgene was induced with 500 µM auxin (Sigma-Aldrich). For centrinone controls, cells were incubated with 125 nM centrinone B (Tocris).

PQBP1-mAID and TUBGCP6-mAID cell line production

PQBP1 gene targeting was performed in DLD-1 cells using CRISPR/Cas9. An sgRNA targeting PQBP1 immediately upstream of its stop codon (5'-CCCGAACCAAGCAGCAGGAT-3') was cloned into the px459 expression vector (48138; Addgene). A donor pUC19 vector was constructed with a mAID-EGFP-P2A-Neo cassette flanked on the 5' end with a 568-bp homology arm and on the 3' end with a 458-bp homology arm. DLD-1 cells were transfected with the px459 and pUC19 donor vector and selected in G418 at 600 µg/ml for 10 d. Expression of PQBP1-mAID-EGFP was confirmed by immunofluorescence, and homozygous tagging was confirmed by immunoblot.

TUBGCP6 gene targeting was performed in DLD-1 cells using CRISPR/Cas9. An sgRNA targeting TUBGCP6 immediately upstream of its stop codon (5'-ACAACCTACTACCAGGACGCC-3') was cloned into the px459 expression vector (48138; Addgene). A donor pUC19 vector was constructed with a mAID-EGFP-P2A-Neo cassette flanked on the 5' end with a 350-bp homology arm and on the 3' end with a 520-bp homology arm. DLD-1 cells were transfected with the px459 and pUC19 donor vector and selected in G418 at 600 µg/ml for 10 d. Expression of TUBGCP6-mAID-EGFP was confirmed by immunofluorescence and homozygous tagging was confirmed by immunoblot.

BioID and mass spectrometry

Stable Flp-In cell lines expressing FLAG-BirA-WBP11 were generated as described above. Expression of FLAG-BirA-WBP11 was induced using 1 µg/ml of tetracycline (Sigma-Aldrich) when the cells were ~40% confluent. After 24 h of tetracycline treatment, cells were given fresh medium with 50 µM biotin for 14–18 h. Cells were lysed in buffer containing 50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 5 mM EDTA, 1 mM DTT, 2% Triton X-100, 1 mM PMSF, and one Roche Protease Inhibitor tablet. Cells were sonicated twice on ice with 30 pulses at 30% duty cycle. An equal volume of 7.4 mM Tris, pH 7.4, was added, and cells were sonicated again on ice with 30 pulses at 30% duty cycle. Cells were centrifuged, and the remaining supernatant was passed over streptavidin agarose beads and rotated at 4°C overnight. Biotinylated proteins were eluted from streptavidin agarose by resuspension in a solution of 2% SDS, 10% glycerol, and 50 mM Tris, pH 8.1, containing 4 mM biotin with heating at 90°C for 20 min. The protein eluates were precipitated using trichloroacetic acid, washed, dried, digested with trypsin to peptides, desalting, and analyzed by high-performance mass spectrometry exactly as described previously (Lyons et al., 2018). Peptide tandem mass spectra were data-searched against a UniProt

(<https://www.uniprot.org>) human proteome database using the Comet search algorithm, filtered to a 1% FDR using the target-decoy strategy, and used to infer protein identifications exactly as described previously (Kettenbach et al., 2018).

Flow cytometry

Cells were incubated for 5 d in the following conditions: tetracycline (1 µg/ml), auxin (500 µM), or tetracycline (1 µg/ml) and centrinone (250 nM). Cells were then prepared for flow cytometry by trypsinizing, centrifuging for 5 min at 400 g⁻¹, and resuspending cell pellets in 1× PBS. Cell suspensions were analyzed on a Guava EasyCyte 6-2L Benchtop Flow Cytometer. The ratio of mCardinal-negative cells to mCardinal-positive cells was calculated for each coculture condition. Statistical analysis was determined using an unpaired *t* test.

Antibody usage and production

For Western blot analysis, proteins were separated via SDS-PAGE, transferred onto nitrocellulose membrane with a Trans-Blot Turbo Transfer System (Bio-Rad), and incubated with the following antibodies diluted into 5% milk: YL1/2 (rat anti- α -tubulin, 1:1,000; Pierce Antibodies), rabbit anti-WBP11 (1:1,000; Thermo Fisher Scientific), mouse anti-SNW1 (1:500; Santa Cruz), rabbit anti-STIL (Holland Lab, described in Moyer et al., 2015), mouse anti-PP1 (E9, 1:200; Santa Cruz), rabbit anti-TUBGCP6 (1:1,000; a gift from J. Luders, Institute for Research in Biomedicine Barcelona, Barcelona, Spain), rabbit anti-SREBF1 (1:1,000; Protein Tech), rabbit anti-RECQL4 (1:1,000; Protein Tech), mouse anti-Vinculin H-10 (1:500; Santa Cruz), and mouse anti-NEDD1 (1:500; Santa Cruz).

For immunofluorescence, 18-mm coverslips were fixed in -20°C 100% methanol for 10 min and blocked at room temperature for 1 h. The block solution consists of 2.5% FBS, 200 mM glycine, and 0.1% Triton X-100 in PBS. Coverslips were incubated with the following antibodies diluted in block solution for 1 h at room temperature in the dark: mouse anti-centrin (EMD Millipore, 1:1,000), centrin-Alexa Fluor 555 (directly labeled rabbit, 1:1,000), CEP192-DyL488 (directly labeled goat, raised against CEP192 aa 1–211, 1:1,000), and γ -tubulin-Alexa Fluor 647 (directly labeled goat, raised against γ -tubulin aa 432–451, 1:1,000). Coverslips were washed in triplicate with PBS containing 0.1% Triton-X (PBST) and then, if required, incubated in secondary antibody diluted in block solution for 1 h at room temperature (Invitrogen). Coverslips were washed in triplicate with PBST then incubated in DAPI diluted in PBST for 3 min and mounted onto slides using ProLong Gold Antifade (Invitrogen).

mRNA-seq data collection and analysis

mRNA was purified from cells using Qiagen RNeasy kit with DNase treatment. Purified mRNA was sent to the Genetic Resources Core Facility at Johns Hopkins School of Medicine, and sequencing was done using paired-end Illumina NextSeq with a read length of 75 bp and 60–80 million reads per sample. Reads were aligned and mapped to hg38 using RSEM. The RNA-seq data from this publication was submitted to the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>) and assigned the accession no. GSE129231.

Differential expression analysis for both genes and isoforms was performed using EBSeq (Leng et al., 2013). For differential gene analysis, hits were considered to be any genes with an expression fold change in the experimental condition that is more than two SDs away from the average expression fold change observed comparing the experimental condition to the control condition. For differential isoform analysis, any genes with only one expressed or detected isoform were excluded from our analysis. We excluded any isoforms for which the FPKM (fragments per kilobase of transcript per million mapped reads) in both conditions (control versus experimental) was <10% of the average FPKM for any given isoform to account for noise. All reads for every detected isoform of a gene were added together to get the total reads. For genes in which there were no reads in one of the two conditions, the gene was excluded from this differential isoform analysis since the gene as a whole is differentially expressed. The proportion of reads for a given gene represented by each isoform was then calculated for both experimental and control conditions. The control condition proportion was subtracted from the experimental condition proportion to get proportion change. Hits were any isoforms where the proportion change was more than two SDs away from the average proportion change.

IRFinder was used to calculate an IRratio that scores the frequency with which an intron is retained in a given mRNA (Middleton et al., 2017). IRratios for introns that failed to meet the IRFinder quality control filter were removed from the analysis. An IRDif score was calculated for each intron by subtracting the IRratio for each intron in the control cells from the IRratio of the same intron in the experimental population. A positive IRDif score corresponds to an intron that was retained more frequently, and a negative IRDif score corresponds to an intron that was spliced more efficiently. Introns with IRDif scores of ≥ 0.1 or ≤ -0.1 were considered hits in our analysis.

To calculate the change in the fraction of spliced mRNA for each gene (Δ Splicing) we used the following formula:

$$\Delta\text{Splicing} = \frac{(1 - \text{IRDif}_{\text{Intron1}}) \times (1 - \text{IRDif}_{\text{Intron2}}) \times (1 - \text{IRDif}_{\text{Intron3}}) \times (1 - \text{IRDif}_{\text{Intron4}})}{(1 - \text{IRDif}_{\text{Intron3}}) \times (1 - \text{IRDif}_{\text{Intron4}})}$$

To validate retained introns, RNA was reverse transcribed using SuperScript IV kit (Invitrogen), and the cDNA was PCR-amplified using the following primers: TUBGCP6, 5'-GCTGTC GACTACTTCTCGTGG-3' and 5'-GCAGGTACTTGAGAGCGAGG-3'; RNF123, 5'-GATGTCTCTGCTTCGGCTGT-3' and 5'-GCTAAG CAGAAACTTGCAGGG-3'; and RECQL4, 5'-GGGCACTCCAATAC AGCTT-3' and 5'-GCTCCAGGTAGCACAGCAAA-3'.

MAXENT splice site scores

5' splice site strength was predicted using MAXENT scores (Yeo and Burge, 2004). The MAXENT framework was generated using large datasets of known human splice sites and takes into account adjacent and nonadjacent dependences. For 5' splice sites, three exonic base pairs and six intronic base pairs flanking the 5' splice site are used, as those positions are generally well conserved in the context of splicing. The splice site model assigns a MAXENT score from -20 to +20, with a higher score meaning a higher probability the sequence is a true splice site.

Online supplemental material

Fig. S1 shows the design of the siRNA screen and the hits obtained from the screen. Fig. S2 shows data supporting WBP11's role in cell proliferation. Fig. S3 shows that PQBP1 is not required for centriole biogenesis. Fig. S4 contains analysis of the RNA-seq data following WBP11 or SNW1 depletion and some follow-up data from this analysis. Fig. S5 contains analysis of some retained introns identified by RNA-seq analysis and follow-up of these hits, particularly of TUBGCP6. Table S1 contains details of the siRNA screen and correlates to Fig. S1. Table S2 contains details of the mass spectrometry analysis and correlates to Fig. 3. Table S3 contains differential gene expression analysis. Table S4 contains differential isoform expression analysis and correlates to Fig. 4, B and C, and Fig. S4, A and B. Table S5 contains IR analysis and correlates to Fig. 4, D and E, and Fig. S4 D. Table S6 contains transcript-wide splicing analysis and correlates to Fig. 4, F and G, and Fig. S4 E. Video 1 shows an untreated WBP11^{AID} cell going through mitosis with H2B-iRFP expressed. Video 2 shows an auxin-treated WBP11^{AID} cell going through mitosis with H2B-iRFP expressed. Video 3 shows an untreated WBP11^{AID} cell going through mitosis with both H2B-iRFP (red) and RFP-tubulin (green) expressed. Video 4 shows an auxin-treated WBP11^{AID} cell going through mitosis with both H2B-iRFP (red) and RFP-tubulin (green) expressed. Video 5 shows a control TUBGCP6^{AID} cell going through mitosis with both H2B-iRFP (red) and RFP-tubulin (green) expressed. Video 6 shows an auxin-treated TUBGCP6^{AID} cell going through mitosis with both H2B-iRFP (red) and RFP-tubulin (green) expressed. Data file 1 contains the source data for the figures. Data file 2 contains information about the statistical tests that were run and their results.

Acknowledgments

We are extremely grateful to Jeremy Nathans, Antony Rosen, and the Johns Hopkins Institute for Basic Biomedical Sciences for providing research support.

This work was supported by the National Institutes of Health (R01GM114119 and R01GM133897) and an American Cancer Society Scholar Grant (RSG-16-156-01-CCG) to A.J. Holland and a National Institutes of Health grant (R01 GM122846) to S.A. Gerber. E.M. Park was funded by a National Institutes of Health training grant (T32GM007445) and a National Science Foundation Graduate Research Fellowship.

The authors declare no competing financial interests.

Author contributions: E.M. Park, P.M. Scott, and K. Clutario performed the majority of the experiments. K.B. Cassidy and S.A. Gerber performed the BioID experiments. K. Zhan assisted with data collection and analysis. E.M. Park, P.M. Scott, K.B. Cassidy, S.A. Gerber, and A.J. Holland designed experiments and analyzed the data. E.M. Park and A.J. Holland wrote the manuscript, and all authors edited it.

Submitted: 30 April 2019

Revised: 24 September 2019

Accepted: 22 October 2019

References

Ahn, E.Y., R.C. DeKelver, M.C. Lo, T.A. Nguyen, S. Matsuura, A. Boyapati, S. Pandit, X.D. Fu, and D.E. Zhang. 2011. SON controls cell-cycle progression by coordinated regulation of RNA splicing. *Mol. Cell.* 42: 185–198. <https://doi.org/10.1016/j.molcel.2011.03.014>

Alves-Cruzeiro, J.M., R. Nogales-Cadenas, and A.D. Pascual-Montano. 2014. CentrosomeDB: a new generation of the centrosomal proteins database for Human and Drosophila melanogaster. *Nucleic Acids Res.* 42(Database issue):D430–D436. <https://doi.org/10.1093/nar/gkt126>

Arquint, C., and E.A. Nigg. 2014. STIL microcephaly mutations interfere with APC/C-mediated degradation and cause centriole amplification. *Curr. Biol.* 24:351–360. <https://doi.org/10.1016/j.cub.2013.12.016>

Arquint, C., A.M. Gabryjontczik, S. Imseng, R. Böhm, E. Sauer, S. Hiller, E.A. Nigg, and T. Maier. 2015. STIL binding to Polo-box 3 of PLK4 regulates centriole duplication. *eLife* 4:e07888. <https://doi.org/10.7554/eLife.07888>

Arquint, C., K.F. Sonnen, Y.D. Stierhof, and E.A. Nigg. 2012. Cell-cycle-regulated expression of STIL controls centriole number in human cells. *J. Cell Sci.* 125:1342–1352. <https://doi.org/10.1242/jcs.099887>

Bahtz, R., J. Seidler, M. Arnold, U. Haselmann-Weiss, C. Antony, W.D. Lehmann, and I. Hoffmann. 2012. GCP6 is a substrate of Plk4 and required for centriole duplication. *J. Cell Sci.* 125:486–496. <https://doi.org/10.1242/jcs.093930>

Balestra, F.R., P. Strnad, I. Flückiger, and P. Gönczy. 2013. Discovering regulators of centriole biogenesis through siRNA-based functional genomics in human cells. *Dev. Cell.* 25:555–571. <https://doi.org/10.1016/j.devcel.2013.05.016>

Bao, J., Y. Yu, J. Chen, Y. He, X. Chen, Z. Ren, C. Xue, L. Liu, Q. Hu, J. Li, et al. 2018. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. *Cell Death Dis.* 9: 1045. <https://doi.org/10.1038/s41419-018-1020-0>

Bettencourt-Dias, M., A. Rodrigues-Martins, L. Carpenter, M. Riparbelli, L. Lehmann, M.K. Gatt, N. Carmo, F. Balloux, G. Callaini, and D.M. Glover. 2005. SAK/PLK4 is required for centriole duplication and flagella development. *Curr. Biol.* 15:2199–2207. <https://doi.org/10.1016/j.cub.2005.11.042>

Braunschweig, U., N.L. Barbosa-Morais, Q. Pan, E.N. Nachman, B. Alipanahi, T. Gonatopoulos-Pouratzis, B. Frey, M. Irimia, and B.J. Blencowe. 2014. Widespread intron retention in mammals functionally tunes transcripts. *Genome Res.* 24:1774–1786. <https://doi.org/10.1101/gr.17790.114>

Buckley, P.T., M.T. Lee, J.Y. Sul, K.Y. Miyashiro, T.J. Bell, S.A. Fisher, J. Kim, and J. Eberwine. 2011. Cytoplasmic intron sequence-retaining transcripts can be dendritically targeted via ID element retrotransposons. *Neuron.* 69:877–884. <https://doi.org/10.1016/j.neuron.2011.02.028>

Cao, J., Y. Shen, L. Zhu, Y. Xu, Y. Zhou, Z. Wu, Y. Li, X. Yan, and X. Zhu. 2012. miR-129-3p controls cilia assembly by regulating CP110 and actin dynamics. *Nat. Cell Biol.* 14:697–706. <https://doi.org/10.1038/ncb2512>

Chavali, P.L., M. Pütz, and F. Gergely. 2014. Small organelle, big responsibility: the role of centrosomes in development and disease. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 369:20130468. <https://doi.org/10.1098/rstb.2013.0468>

Coelho, P.A., L. Bury, M.N. Shahbazi, K. Liakath-Ali, P.H. Tate, S. Wormald, C.J. Hindley, M. Huch, J. Archer, W.C. Skarnes, et al. 2015. Overexpression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse. *Open Biol.* 5:150209. <https://doi.org/10.1098/rsob.150209>

Craggs, G., P.M. Finan, D. Lawson, J. Wingfield, T. Perera, S. Gadher, N.F. Totty, and S. Kellie. 2001. A nuclear SH3 domain-binding protein that colocalizes with mRNA splicing factors and intermediate filament-containing perinuclear networks. *J. Biol. Chem.* 276:30552–30560. <https://doi.org/10.1074/jbc.M103142200>

Cunha-Ferreira, I., I. Bento, A. Pimenta-Marques, S.C. Jana, M. Lince-Faria, P. Duarte, J. Borrego-Pinto, S. Gilberto, T. Amado, D. Brito, et al. 2013. Regulation of autophosphorylation controls PLK4 self-destruction and centriole number. *Curr. Biol.* 23:2245–2254. <https://doi.org/10.1016/j.cub.2013.09.037>

Dahl, K.D., D.G. Sankaran, B.A. Bayless, M.E. Pinter, D.F. Galati, L.R. Heasley, T.H. Giddings Jr., and C.G. Pearson. 2015. A Short CEPI35 Splice Isoform Controls Centriole Duplication. *Curr. Biol.* 25:2591–2596. <https://doi.org/10.1016/j.cub.2015.08.039>

Dominguez, D., Y.H. Tsai, R. Weatheritt, Y. Wang, B.J. Blencowe, and Z. Wang. 2016. An extensive program of periodic alternative splicing linked to cell cycle progression. *eLife* 5:e10288. <https://doi.org/10.7554/eLife.10288>

Dzhindzhev, N.S., G. Tzolovsky, Z. Lipinszki, S. Schneider, R. Lattao, J. Fu, J. Debski, M. Dadlez, and D.M. Glover. 2014. Plk4 phosphorylates Ana2 to trigger Sas6 recruitment and procentriole formation. *Curr. Biol.* 24: 2526–2532. <https://doi.org/10.1016/j.cub.2014.08.061>

Dzhindzhev, N.S., G. Tzolovsky, Z. Lipinszki, M. Abdelaziz, J. Debski, M. Dadlez, and D.M. Glover. 2017. Two-step phosphorylation of Ana2 by Plk4 is required for the sequential loading of Ana2 and Sas6 to initiate procentriole formation. *Open Biol.* 7:170247. <https://doi.org/10.1098/rsob.170247>

Farach, L.S., M.E. Little, A.L. Duker, C.V. Logan, A. Jackson, J.T. Hecht, and M. Bober. 2018. The expanding phenotype of RNU4ATAC pathogenic variants to Lowry Wood syndrome. *Am. J. Med. Genet. A.* 176:465–469. <https://doi.org/10.1002/ajmg.a.38581>

Farache, D., L. Emorine, L. Haren, and A. Merdes. 2018. Assembly and regulation of γ -tubulin complexes. *Open Biol.* 8:170266. <https://doi.org/10.1098/rsob.170266>

Firat-Karalar, E.N., and T. Stearns. 2014. The centriole duplication cycle. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 369:20130460. <https://doi.org/10.1098/rstb.2013.0460>

Frank, D., and C. Guthrie. 1992. An essential splicing factor, SLU7, mediates 3' splice site choice in yeast. *Genes Dev.* 6:2112–2124. <https://doi.org/10.1101/gad.6.11.2112>

Gönczy, P. 2012. Towards a molecular architecture of centriole assembly. *Nat. Rev. Mol. Cell Biol.* 13:425–435. <https://doi.org/10.1038/nrm3373>

Grainger, R.J., and J.D. Beggs. 2005. Prp8 protein: at the heart of the spliceosome. *RNA* 11:533–557. <https://doi.org/10.1261/rna.2220705>

Guderian, G., J. Westendorf, A. Uldschmid, and E.A. Nigg. 2010. Plk4 trans-autophosphorylation regulates centriole number by controlling betaTrCP-mediated degradation. *J. Cell Sci.* 123:2163–2169. <https://doi.org/10.1242/jcs.068502>

Habedanck, R., Y.D. Stierhof, C.J. Wilkinson, and E.A. Nigg. 2005. The Polo kinase Plk4 functions in centriole duplication. *Nat. Cell Biol.* 7:1140–1146. <https://doi.org/10.1038/ncb1320>

He, H., S. Liyanarachchi, K. Akagi, R. Nagy, J. Li, R.C. Dietrich, W. Li, N. Sebastian, B. Wen, B. Xin, et al. 2011. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. *Science* 332:238–240. <https://doi.org/10.1126/science.1200587>

Holland, A.J., D. Fachinetti, J.S. Han, and D.W. Cleveland. 2012. Inducible, reversible system for the rapid and complete degradation of proteins in mammalian cells. *Proc. Natl. Acad. Sci. USA* 109:E3350–E3357. <https://doi.org/10.1073/pnas.1216880109>

Holland, A.J., W. Lan, S. Niessen, H. Hoover, and D.W. Cleveland. 2010. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. *J. Cell Biol.* 188:191–198. <https://doi.org/10.1083/jcb.200911102>

Kettenbach, A.N., K.A. Schlosser, S.P. Lyons, I. Nasa, J. Gui, M.E. Adamo, and S.A. Gerber. 2018. Global assessment of its network dynamics reveals that the kinase Plk1 inhibits the phosphatase PP6 to promote Aurora A activity. *Sci. Signal.* 11:eaaoq1441.

Kim, T.S., J.E. Park, A. Shukla, S. Choi, R.N. Murugan, J.H. Lee, M. Ahn, K. Rhee, J.K. Bang, B.Y. Kim, et al. 2013. Hierarchical recruitment of Plk4 and regulation of centriole biogenesis by two centrosomal scaffolds, Cep192 and Cep152. *Proc. Natl. Acad. Sci. USA* 110:E4849–E4857. <https://doi.org/10.1073/pnas.1319656110>

Klebba, J.E., D.W. Buster, A.L. Nguyen, S. Swatkoski, M. Gucek, N.M. Rusan, and G.C. Rogers. 2013. Polo-like kinase 4 autodestructs by generating its Slimb-binding phosphodegron. *Curr. Biol.* 23:2255–2261. <https://doi.org/10.1016/j.cub.2013.09.019>

Komuro, A., M. Saeki, and S. Kato. 1999. Association of two nuclear proteins, Npw38 and NpwBP, via the interaction between the WW domain and a novel proline-rich motif containing glycine and arginine. *J. Biol. Chem.* 274:36513–36519. <https://doi.org/10.1074/jbc.274.51.36513>

Kratz, A.S., F. Bärenz, K.T. Richter, and I. Hoffmann. 2015. Plk4-dependent phosphorylation of STIL is required for centriole duplication. *Biol. Open.* 4:370–377. <https://doi.org/10.1242/bio.201411023>

Leda, M., A.J. Holland, and A.B. Goryachev. 2018. Autoamplification and Competition Drive Symmetry Breaking: Initiation of Centriole Duplication by the PLK4-STIL Network. *iScience* 8:222–235. <https://doi.org/10.1016/j.isci.2018.10.003>

Leng, N., J.A. Dawson, J.A. Thomson, V. Ruotti, A.I. Rissman, B.M. Smits, J.D. Haag, M.N. Gould, R.M. Stewart, and C. Kendziora. 2013. EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. *Bioinformatics* 29:1035–1043. <https://doi.org/10.1093/bioinformatics/btt087>

Levine, M.S., B. Bakker, B. Boeckx, J. Moyett, J. Lu, B. Vitre, D.C. Spierings, P.M. Lansdorp, D.W. Cleveland, D. Lambrechts, et al. 2017. Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in

Mammals. *Dev. Cell.* 40:313–322.e5. <https://doi.org/10.1016/j.devcel.2016.12.022>

Llorian, M., M. Beullens, I. Andrés, J.M. Ortiz, and M. Bollen. 2004. SIPP1, a novel pre-mRNA splicing factor and interactor of protein phosphatase 1. *Biochem. J.* 378:229–238. <https://doi.org/10.1042/bj20030950>

Llorian, M., M. Beullens, B. Lesage, E. Nicolaescu, L. Beke, W. Landuyt, J.M. Ortiz, and M. Bollen. 2005. Nucleocytoplasmic shuttling of the splicing factor SIPP1. *J. Biol. Chem.* 280:38862–38869. <https://doi.org/10.1074/jbc.M509185200>

Lopes, C.A., S.C. Jana, I. Cunha-Ferreira, S. Zitouni, I. Bento, P. Duarte, S. Gilberto, F. Freixo, A. Guerrero, M. Francia, et al. 2015. PLK4 trans-Autoactivation Controls Centriole Biogenesis in Space. *Dev. Cell.* 35: 222–235. <https://doi.org/10.1016/j.devcel.2015.09.020>

Lyons, S.P., N.P. Jenkins, I. Nasa, M.S. Choy, M.E. Adamo, R. Page, W. Peti, G.B. Moorhead, and A.N. Kettenbach. 2018. A quantitative chemical proteomic strategy for profiling phosphoprotein phosphatases from yeast to humans. *Mol. Cell. Proteomics.* 17:2448–2461. <https://doi.org/10.1074/mcp.RA118.000822>

Merico, D., M. Roifman, U. Braunschweig, R.K. Yuen, R. Alexandrova, A. Bates, B. Reid, T. Nalpathamkalam, Z. Wang, B. Thiruvahindrapuram, et al. 2015. Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing. *Nat. Commun.* 6:8718. <https://doi.org/10.1038/ncomms9718>

Middleton, R., D. Gao, A. Thomas, B. Singh, A. Au, J.J. Wong, A. Boman, B. Cossen, E. Eyras, J.E. Rasko, and W. Ritchie. 2017. IRFinder: assessing the impact of intron retention on mammalian gene expression. *Genome Biol.* 18:51. <https://doi.org/10.1186/s13059-017-1184-4>

Moyer, T.C., and A.J. Holland. 2019. PLK4 promotes centriole duplication by phosphorylating STIL to link the procentriole cartwheel to the microtubule wall. *eLife.* 8:e46054. <https://doi.org/10.7554/eLife.46054>

Moyer, T.C., K.M. Clutario, B.G. Lambrus, V. Daggubati, and A.J. Holland. 2015. Binding of STIL to Plk4 activates kinase activity to promote centriole assembly. *J. Cell Biol.* 209:863–878. <https://doi.org/10.1083/jcb.201502088>

Munding, E.M., L. Shiu, S. Katzman, J.P. Donohue, and M. Ares Jr. 2013. Competition between pre-mRNAs for the splicing machinery drives global regulation of splicing. *Mol. Cell.* 51:338–348. <https://doi.org/10.1016/j.molcel.2013.06.012>

Murthy, K.G., and J.L. Manley. 1995. The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3'-end formation. *Genes Dev.* 9:2672–2683. <https://doi.org/10.1101/gad.9.21.2672>

Nigg, E.A., and A.J. Holland. 2018. Once and only once: mechanisms of centriole duplication and their deregulation in disease. *Nat. Rev. Mol. Cell Biol.* 19:297–312. <https://doi.org/10.1038/nrm.2017.127>

Nishimura, K., T. Fukagawa, H. Takisawa, T. Kakimoto, and M. Kanemaki. 2009. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. *Nat. Methods.* 6:917–922. <https://doi.org/10.1038/nmeth.1401>

Ohta, M., T. Ashikawa, Y. Nozaki, H. Kozuka-Hata, H. Goto, M. Inagaki, M. Oyama, and D. Kitagawa. 2014. Direct interaction of Plk4 with STIL ensures formation of a single procentriole per parental centriole. *Nat. Commun.* 5:5267. <https://doi.org/10.1038/ncomms6267>

Pellacani, C., E. Bucciarelli, F. Renda, D. Hayward, A. Palena, J. Chen, S. Bonaccorsi, J.G. Wakefield, M. Gatti, and M.P. Somma. 2018. Splicing factors Sf3A2 and Prp31 have direct roles in mitotic chromosome segregation. *eLife.* 7:e40325. <https://doi.org/10.7554/eLife.40325>

Roca, X., A.R. Krainer, and I.C. Eperon. 2013. Pick one, but be quick: 5' splice sites and the problems of too many choices. *Genes Dev.* 27:129–144. <https://doi.org/10.1101/gad.209759.112>

Roux, K.J., D.I. Kim, M. Raida, and B. Burke. 2012. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. *J. Cell Biol.* 196:801–810. <https://doi.org/10.1083/jcb.201112098>

Sakabe, N.J., and S.J. de Souza. 2007. Sequence features responsible for intron retention in human. *BMC Genomics.* 8:59. <https://doi.org/10.1186/1471-2164-8-59>

Ganapathi Sankaran, D., A.J. Stemmer-Wolf, and C.G. Pearson. 2019. CEP135 isoform dysregulation promotes centrosome amplification in breast cancer cells. *Mol. Biol. Cell.* 30:1230–1244. <https://doi.org/10.1091/mbc.E18-10-0674>

Serçin, Ö., J.C. Larsimont, A.E. Karambelas, V. Marthiens, V. Moers, B. Boeckx, M. Le Mercier, D. Lambrechts, R. Basto, and C. Blanpain. 2016. Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis. *Nat. Cell Biol.* 18:100–110. <https://doi.org/10.1038/ncb3270>

Song, R., P. Walentek, N. Sponer, A. Klimke, J.S. Lee, G. Dixon, R. Harland, Y. Wan, P. Lishko, M. Lize, et al. 2014. miR-34/449 miRNAs are required for motile ciliogenesis by repressing cpl10. *Nature.* 510:115–120. <https://doi.org/10.1038/nature13413>

Sonnen, K.F., L. Schermelleh, H. Leonhardt, and E.A. Nigg. 2012. 3D-structured illumination microscopy provides novel insight into architecture of human centrosomes. *Biol. Open.* 1:965–976. <https://doi.org/10.1242/bio.20122337>

Strnad, P., S. Leidel, T. Vinogradova, U. Euteneuer, A. Khodjakov, and P. Gönczy. 2007. Regulated HsSAS-6 levels ensure formation of a single procentriole per centriole during the centrosome duplication cycle. *Dev. Cell.* 13:203–213. <https://doi.org/10.1016/j.devcel.2007.07.004>

Sundaramoorthy, S., M.D. Vázquez-Novelle, S. Lekomtsev, M. Howell, and M. Petronczki. 2014. Functional genomics identifies a requirement of pre-mRNA splicing factors for sister chromatid cohesion. *EMBO J.* 33: 2623–2642. <https://doi.org/10.15252/embj.201488244>

Tang, C.J.C., S.Y. Lin, W.B. Hsu, Y.N. Lin, C.T. Wu, Y.C. Lin, C.W. Chang, K.S. Wu, and T.K. Tang. 2011. The human microcephaly protein STIL interacts with CPAP and is required for procentriole formation. *EMBO J.* 30:4790–4804. <https://doi.org/10.1038/embj.2011.378>

van der Lelij, P., R.R. Stocsits, R. Ladurner, G. Petzold, E. Kreidl, B. Koch, J. Schmitz, B. Neumann, J. Ellenberg, and J.M. Peters. 2014. SNW1 enables sister chromatid cohesion by mediating the splicing of sororin and APC2 pre-mRNAs. *EMBO J.* 33:2643–2658. <https://doi.org/10.15252/embj.201488202>

Vulprecht, J., A. David, A. Tibelius, A. Castiel, G. Konotop, F. Liu, F. Bestvater, M.S. Raab, H. Zentgraf, S. Izraeli, and A. Krämer. 2012. STIL is required for centriole duplication in human cells. *J. Cell Sci.* 125:1353–1362. <https://doi.org/10.1242/jcs.104109>

Wickramasinghe, V.O., M. González-Porta, D. Perera, A.R. Bartolozzi, C.R. Sibley, M. Hallegger, J. Ule, J.C. Marioni, and A.R. Venkitaraman. 2015. Regulation of constitutive and alternative mRNA splicing across the human transcriptome by PRPF8 is determined by 5' splice site strength. *Genome Biol.* 16:201. <https://doi.org/10.1186/s13059-015-0749-3>

Wong, J.J., W. Ritchie, O.A. Ebner, M. Selbach, J.W. Wong, Y. Huang, D. Gao, N. Pinello, M. Gonzalez, K. Baidya, et al. 2013. Orchestrated intron retention regulates normal granulocyte differentiation. *Cell.* 154:583–595. <https://doi.org/10.1016/j.cell.2013.06.052>

Yeo, G., and C.B. Burge. 2004. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J. Comput. Biol.* 11: 377–394. <https://doi.org/10.1089/1066527041410418>

Supplemental material

Park et al., <https://doi.org/10.1083/jcb.201904203>




Figure S1. siRNA screen to identify novel phosphatase or phosphatase-interacting proteins required for centriole biogenesis. (A) Schematic representation of the screen design. A SMARTpool of four siRNAs targeting each gene was transfected into DLD-1 cells. 48 h after siRNA transfection, centriole number was analyzed in mitotic cells. A total of 254 genes were screened. Scale bars represent 5 μ m; 1 μ m in inset. **(B)** Graph shows the fraction of cells with two or fewer centrioles in mitosis. Each point represents a single gene. Raw data are displayed in Table S1. Colors indicate one, two, or three SDs above the level of centriole underduplication observed in untransfected DLD-1 cells (red line). Hits were considered as genes that are more than two SDs above the control. More than 25 mitotic cells per siRNA were analyzed. **(C)** Secondary validation of the top hits from the initial screen in DLD-1 cells. Colors indicate one, two, or three SDs above the level of centriole underduplication observed in untransfected DLD-1 cells (red line). $n = 1$, ≥ 25 mitotic cells per siRNA were analyzed. **(D)** Validation of the top hits from the initial screen in HeLa cells. Colors indicate one, two, or three SDs above the level of centriole underduplication observed in untransfected DLD-1 cells (red line). $n \geq 1$, ≥ 25 mitotic cells per siRNA were analyzed. Error bars represent SD. **(E)** Validation of the top hits from the initial screen in HCT116 cells. Colors indicate one, two, or three SDs above the level of centriole underduplication observed in untransfected DLD-1 cells (red line). $n \geq 1$, ≥ 25 mitotic cells per siRNA were analyzed. Error bars represent SD.




Figure S2. Cells lacking WBP11 show major growth defects. **(A)** Immunoblot showing expression levels of WBP11 72 h after siRNA transfection in RPE-1 cells. **(B)** Quantification of centriole number in mitotic RPE-1 cells 72 h after depletion of WBP11 with SMARTpool siRNA. $n = 3$, ≥ 50 cells per experiment. Error bars represent SD. **(C)** Immunoblot showing coimmunoprecipitation (IP) of HA-PP1 α , β , and γ with MycGFP-WBP11. **(D)** Schematic of WBP11 showing its functional domains and the two PP1 binding sites. **(E)** Quantification of the intensity of the WBP11-mAID-EGFP transgene measured from time-lapse videos of WBP11^{AID} cells after auxin addition. $n = 3$, 20 cells analyzed per point per replicate. Error bars represent SEM. **(F)** Growth assay showing the fold increase in cell number of DLD-1 LacZeo cells treated with tetracycline, auxin, or centrinone. Data are means \pm SEM, $n = 3$ (untreated $n = 2$), performed in triplicate. **(G)** Quantification of mitotic duration from time-lapse videos of untreated WBP11^{AID} cells expressing H2B-iRFP. The x axis shows how long after the beginning of filming WBP11^{AID} cells entered into mitosis. Green dots mark cells that completed mitosis normally and red dots mark cells that underwent mitotic errors. $n = 3$, ≥ 100 cells per experiment. **(H)** Representative frames from videos of WBP11^{AID} cells stably expressing H2B-iRFP. Cells were either untreated or treated with auxin to induce WBP11^{AID} destruction. Scale bars represent 10 μ m.




Figure S3. PQBP1 is not required for centriole biogenesis. **(A)** Schematic depicting the strategy for endogenous tagging of the PQBP1 gene. Cells were cotransfected with a plasmid encoding the repair template and a plasmid that expresses Cas9 and an sgRNA. Homozygous PQBP1-AID-EGFP clones were identified by immunoblot. **(B)** Representative images of a control cell line in which PQBP1 was not tagged (PQBP1^{WT}) and a cell line in which both PQBP1 alleles were endogenously tagged with mAID-EGFP (PQBP1^{AID}). Scale bars represent 5 μ m. **(C)** Immunoblot showing expression of endogenously tagged PQBP1-mAID-EGFP in PQBP1^{AID} cells and its degradation after auxin addition. PQBP1^{WT} cells are shown as a control. **(D)** Representative images of control cells (PQBP1^{WT}) and cells with endogenously tagged PQBP1-mAID-EGFP (PQBP1^{AID}). Cells were either untreated or treated with auxin to induce PQBP1^{AID} destruction. Scale bars represent 5 μ m; 1 μ m in zoomed-in regions. **(E)** Quantification of centriole number in mitotic cells after 48 h of PQBP1-mAID-EGFP degradation by auxin or PLK4 inhibition by centrinone. $n = 3$, ≥ 50 cells per experiment. Error bars represent SD. **(F)** Clonogenic growth assay of the PQBP1^{AID} cell line compared with a nontransduced cell line (Ctl) and to a transduced but not tagged cell line (PQBP1^{WT}). $n = 4$. Unpaired parametric t test: ***, $P = 0.0007$; ****, $P < 0.0001$. Error bars represent SD.




Figure S4. WBP11 and SNW1 are required for the correct splicing of a common set of pre-mRNAs. (A) Overlapping hits for isoforms with expression increased more than two SDs following WBP11 or SNW1 RNAi or WBP11 degradation with auxin. A set of 72 isoforms that depend on both WBP11 and SNW1 for appropriate expression were identified. (B) Overlapping hits for isoforms with expression decreased more than two SDs following WBP11 or SNW1 RNAi or WBP11 degradation with auxin. A set of 86 isoforms that depend on both WBP11 and SNW1 for appropriate expression were identified. (C) Immunoblot showing NEDD1 protein levels after siRNA-mediated depletion of WBP11. (D) Overlapping hits for retained introns with an IRDif score of ≥ 0.1 following WBP11 or SNW1 RNAi or WBP11 degradation with auxin. A set of 145 introns that depend on WBP11 and SNW1 for efficient splicing were identified. (E) Overlapping hits for the genes that experienced a greater than three SD decrease of correctly spliced mRNA after WBP11 or SNW1 RNAi or WBP11 degradation with auxin. A set of 23 genes that depend on WBP11 and SNW1 for efficient splicing were identified. (F) Quantification of centriole number in mitotic cells 72 h after depletion of SNW1 with one of four independent siRNAs. $n = 3, \geq 50$ cells per experiment. Error bars represent SD. (G) Quantification of centriole number in mitotic cells 72 h after depletion of WBP11 by siRNA in TUBGCP6^{AID} cells. TUBGCP6^{AID} was degraded by auxin where indicated. $n = 3, \geq 50$ cells per experiment. Error bars represent SD.







Figure S5. WBP11 and SNW1 are required for the correct splicing of a subset of introns. (A) A region of the *RNF123* gene is aligned to IGV reads to highlight retained introns (*) observed after loss of WBP11 or SNW1. *RNF123* requires WBP11 and, to a lesser extent, SNW1 for efficient splicing of one of its introns (*). (B) A region of the *RECQL4* gene is aligned to IGV reads to highlight retained introns (*) observed after loss of WBP11 or SNW1. *RECQL4* requires WBP11 and SNW1 for efficient splicing of some introns (*). Note that some introns require SNW1, but not WBP11, for efficient splicing. (C) A region of the *SREBF1* gene is aligned to IGV reads to highlight retained introns (*) observed after loss of WBP11 or SNW1. *SREBF1* requires WBP11 and SNW1 for efficient splicing of some introns (*). Note that some introns require SNW1, but not WBP11, for efficient splicing. (D) Immunoblot showing expression levels of RECQL4 and SREBF1 after 72 h of SNW1 or WBP11 siRNA knockdown. (E) Immunoblot showing expression levels of RECQL4 and SREBF1 in WBP11^{WT} and WBP11^{AID} cells at 48 h after auxin addition. (F) Immunoblot showing TUBGCP6 expression in TUBGCP6^{AID} cells expressing a FLAG-TUBGCP6 transgene. (G) Quantification of centriole number in mitotic TUBGCP6^{AID} cells 24 h after auxin addition. TUBGCP6^{AID} cells with or without expression of a FLAG-TUBGCP6 transgene were used. Data are shown alongside the TUBGCP6^{AID} data from Fig. 7 C for comparison. $n = 3, 50$ cells per experiment. Error bars represent SD. (H) Graph showing the percentage of mitotic cells with three to four centrioles after 72 h of WBP11 depletion by siRNA. Expression of the FLAG-TUBGCP6 was induced by addition of doxycycline where indicated. $n = 3, 50$ cells/experiment. Error bars represent SD.




Video 1. **Untreated WBP11^{AID} cell expressing H2B-iRFP.** Still images are represented in Fig. S2 H. One frame captured every 5 min; displayed at 3 frames/s.




Video 2. **Auxin-treated WBP11^{AID} cell expressing H2B-iRFP.** Still images are represented in Fig. S2 H. One frame captured every 5 min; displayed at 3 frames/s.




Video 3. **Untreated WBP11^{AID} cell co-expressing H2B-iRFP (red) and RFP-tubulin (green).** Still images are represented in Fig. 2 H. One frame captured every 5 min; displayed at 3 frames/s.



Video 4. **Auxin-treated WBP11^{AID} cell co-expressing H2B-iRFP (red) and RFP-tubulin (green).** Still images are represented in Fig. 2 H. One frame captured every 5 min; displayed at 3 frames/s.



Video 5. **Untreated TUBGCP6^{AID} cell co-expressing H2B-iRFP (red) and RFP-tubulin (green).** Still images are represented in Fig. 7 D. One frame captured every 5 min; displayed at 3 frames/s.



Video 6. **Auxin-treated TUBGCP6^{AID} cell co-expressing H2B-iRFP (red) and RFP-tubulin (green).** Still images are represented in Fig. 7 D. One frame captured every 5 min; displayed at 3 frames/s.

Table S1 lists phosphatases and their associated proteins that were knocked down in the siRNA screen. The first tab shows the siRNA sequences used to knockdown each protein. A SMARTpool of four siRNAs per gene was used for each knockdown. The second tab shows the percentage of mitotic cells with the indicated number of centrioles for each gene that was knocked down in the primary screen. Tabs three to five show the secondary screen of the top hits from the primary data, performed in DLD-1, HeLa, and HCT116 cells.

Table S2 shows proteins identified in the WBP11 proximity interactome. The first four tabs show four independent experiments of the WBP11-BirA proximity-dependent biotinylation. Proteins found to be biotinylated in the WBP11-BirA sample and control FLAG-BirA sample are indicated in the table, along with the number of peptides identified. Proteins with an enrichment ratio greater than five are highlighted in yellow. The final tab lists proteins that were found in at least three of the four biological replicates with an enrichment ratio greater than five.

Table S3 provides the differential expression analysis used to determine the degree to which a transcript is downregulated following protein depletion. Each tab of the table relates to cells depleted of WBP11 by RNAi for 72 h, cells depleted of WBP11 by auxin for 48 h, or cells depleted of SNW1 by RNAi for 72 h. The fold change in mRNA expression level was calculated using EBSeq PostFC, which takes into consideration both the raw fold change and the total number of reads. Proteins highlighted in red and blue are upregulated or downregulated by more than two SDs, respectively. The final tab shows those genes in which there was a greater than two SD decrease in expression in all three data sets.

Table S4 provides the differential expression analysis used to determine the degree to which isoform expression is altered following protein depletion. The first three tabs of the table relates to cells depleted of WBP11 by RNAi for 72 h, cells depleted of WBP11 by auxin for 48 h, or cells depleted of SNW1 by RNAi for 72 h. The accession number correlating to each isoform is shown next to the gene name. The expected counts and fold change in mRNA expression level were calculated using EBSeq PostFC. The total reads columns (H and I) are a summation of the reads for all isoforms of each gene. The proportion (J and K) was calculated by dividing the expected read counts of the indicated isoform (C and D) by the total number of read counts for that gene (H and I), and corresponds to the proportion of total reads for the gene that are accounted for by the indicated isoform. Δ Isoform is the difference between experimental and control proportions. Gene change is the total number of reads in the experimental condition over the control condition (H over I). Isoforms highlighted in red and blue have a Δ Isoform value that is upregulated or downregulated by more than two SDs, respectively. The final tab shows those isoforms in which there was a more than two SD change of mRNA expression after WBP11 RNAi or WBP11 degradation with auxin.

Table S5 shows RNA-seq analyses using IRFinder identified introns that are selectively retained following WBP11 or SNW1 depletion. The first three tabs show RNA-seq analysis for cells depleted of WBP11 by RNAi for 72 h, cells depleted of WBP11 by auxin for 48 h, or cells depleted of SNW1 by RNAi for 72 h. The fourth tab shows introns retained in all three samples. The introns are sorted by increasing amount retained in the experimental condition, as calculated by IRDif. Condition A is the depleted sample, and condition B is the control. The IRratio refers to the percentage of transcripts in each condition that contains the indicated intron. IRDif was calculated as described in the text by subtracting the IRratio of the control (B-IRratio) from the IRratio of the depleted sample (A-IRratio). We then used this difference in the percentage of unspliced transcripts to calculate the probability that a particular intron will be correctly spliced under the indicated experimental conditions (Probability_Correct), which is equal to one minus the IRDif for that intron. Finally, MAXENT refers to the splice site strength calculated using MaxEntScan (Christopher Burge Laboratory). Retained introns with an IRDif of ≥ 0.1 are highlighted in red, while introns that show increased splicing with an IRDif score of -0.1 or less are highlighted in blue.

Table S6 shows RNA-seq analyses used to determine the degree to which a transcript is misspliced following protein depletion. Each tab of the table relates to cells depleted of WBP11 by RNAi for 72 h, cells depleted of WBP11 by auxin for 48 h, or cells depleted of SNW1 by RNAi for 72 h. The percentage change in fraction of spliced mRNA was calculated using the IRDif for each intron within a transcript, as described in Materials and methods. The final tab shows those genes in which there was a greater than three SD decrease of correctly spliced mRNA after WBP11 or SNW1 RNAi or WBP11 degradation with auxin.

Two data files are provided online. The first data file contains the source data for the figures. The second data file contains information about the statistical tests that were run and their results.

Reference

Christopher Burge Laboratory. MaxEntScan:score5ss for human 5' splice sites. Available at: http://hollywood.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html (accessed November 14, 2018).